Trial Outcomes & Findings for DIA_CENTRAL:T2D Treatment Pattern in Central Europe (NCT NCT03807440)
NCT ID: NCT03807440
Last Updated: 2023-12-01
Results Overview
Baseline characteristic: Number of patients in each category of gender according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by endocrinologist is reported. The reported categories of gender are: * Female * Male
Recruitment status
COMPLETED
Target enrollment
4083 participants
Primary outcome timeframe
At study index date 1 (i.e. between September 2018 and December 2018).
Results posted on
2023-12-01
Participant Flow
This was a non-interventional, multi-country, multi-site study using existing data from medical records to evaluate treatment pattern of Type 2 Diabetes (T2D) patients under routine conditions. It was conducted in medical practices in Central Eastern Europe (CEE) countries (Bulgaria, Czech Republic, Hungary, Poland, Russian Federation). Healthcare professionals (HCPs) of different specialties involved in treatment of T2D patients participated in this study. In this study .
Only subjects that met all inclusion and none of the exclusion criteria were included. 4083 patients were screened, thereof 28 could not be included in the prescribed patient set (PPS).
Participant milestones
| Measure |
T2D Patients From Central Eastern Europe
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) between September 2018 and December 2018 (study index date 1).
|
|---|---|
|
Overall Study
STARTED
|
4055
|
|
Overall Study
COMPLETED
|
3618
|
|
Overall Study
NOT COMPLETED
|
437
|
Reasons for withdrawal
| Measure |
T2D Patients From Central Eastern Europe
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) between September 2018 and December 2018 (study index date 1).
|
|---|---|
|
Overall Study
No documentation of index date 2
|
320
|
|
Overall Study
No informed consent for index date 2
|
117
|
Baseline Characteristics
Prescribed patient set (PPS): All patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective Type 2 diabetes (T2D) medication and whose documentation was electronically signed by the physician. Only participants with non-missing results are reported.
Baseline characteristics by cohort
| Measure |
T2D Patients From Central Eastern Europe
n=4055 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) between September 2018 and December 2018 (study index date 1).
|
|---|---|
|
Age, Continuous
|
63.1 Years
STANDARD_DEVIATION 10.2 • n=4055 Participants
|
|
Sex: Female, Male
Female
|
1993 Participants
n=4055 Participants
|
|
Sex: Female, Male
Male
|
2062 Participants
n=4055 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=4055 Participants
|
|
Race (NIH/OMB)
Asian
|
0 Participants
n=4055 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=4055 Participants
|
|
Race (NIH/OMB)
Black or African American
|
27 Participants
n=4055 Participants
|
|
Race (NIH/OMB)
White
|
4028 Participants
n=4055 Participants
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=4055 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=4055 Participants
|
|
Height
|
169.2 centimeter (cm)
STANDARD_DEVIATION 9.5 • n=4055 Participants
|
|
Weight
|
94.4 kilogram (kg)
STANDARD_DEVIATION 18.8 • n=4055 Participants
|
|
Body Mass Index (BMI)
|
32.9 kilogram/meter^2 (kg/m^2)
STANDARD_DEVIATION 5.8 • n=4055 Participants
|
|
Socioeconomic factor: Employment status
Employed
|
1930 Participants
n=4055 Participants
|
|
Socioeconomic factor: Employment status
Not employed
|
1889 Participants
n=4055 Participants
|
|
Socioeconomic factor: Employment status
Unknown
|
236 Participants
n=4055 Participants
|
|
Socioeconomic factor: Family status
Single
|
278 Participants
n=4055 Participants
|
|
Socioeconomic factor: Family status
Married
|
2670 Participants
n=4055 Participants
|
|
Socioeconomic factor: Family status
Divorced
|
211 Participants
n=4055 Participants
|
|
Socioeconomic factor: Family status
Widowed
|
340 Participants
n=4055 Participants
|
|
Socioeconomic factor: Family status
Unknown
|
556 Participants
n=4055 Participants
|
|
Socioeconomic factor: Insurance status
Not insured
|
77 Participants
n=4055 Participants
|
|
Socioeconomic factor: Insurance status
Statutory insured
|
3655 Participants
n=4055 Participants
|
|
Socioeconomic factor: Insurance status
Privately insured
|
153 Participants
n=4055 Participants
|
|
Socioeconomic factor: Insurance status
Unknown
|
170 Participants
n=4055 Participants
|
|
Risk factor for CVD and CKD: Body Mass Index (BMI) categorical
Being obese
|
2755 Participants
n=4055 Participants
|
|
Risk factor for CVD and CKD: Body Mass Index (BMI) categorical
Being overweight
|
1086 Participants
n=4055 Participants
|
|
Risk factor for CVD and CKD: Body Mass Index (BMI) categorical
Being normal
|
212 Participants
n=4055 Participants
|
|
Risk factor for CVD and CKD: Body Mass Index (BMI) categorical
Being underweight
|
2 Participants
n=4055 Participants
|
|
Risk factor for CVD and CKD: Hypertension
Yes
|
3432 Participants
n=4055 Participants
|
|
Risk factor for CVD and CKD: Hypertension
No
|
589 Participants
n=4055 Participants
|
|
Risk factor for CVD and CKD: Hypertension
Unknown
|
34 Participants
n=4055 Participants
|
|
Risk factor for CVD and CKD: Tobacco smoking
Current smoker
|
664 Participants
n=4055 Participants
|
|
Risk factor for CVD and CKD: Tobacco smoking
Ex-smoker
|
933 Participants
n=4055 Participants
|
|
Risk factor for CVD and CKD: Tobacco smoking
Never smoker
|
2123 Participants
n=4055 Participants
|
|
Risk factor for CVD and CKD: Tobacco smoking
Unknown
|
335 Participants
n=4055 Participants
|
|
Risk factor for CVD and CKD: Being physically inactive
Yes
|
2048 Participants
n=4055 Participants
|
|
Risk factor for CVD and CKD: Being physically inactive
No
|
1736 Participants
n=4055 Participants
|
|
Risk factor for CVD and CKD: Being physically inactive
Unknown
|
271 Participants
n=4055 Participants
|
|
Family history of early heart and kidney disease
Family history of early heart disease · Yes
|
1132 Participants
n=4055 Participants
|
|
Family history of early heart and kidney disease
Family history of early heart disease · No
|
1945 Participants
n=4055 Participants
|
|
Family history of early heart and kidney disease
Family history of early heart disease · Unknown
|
978 Participants
n=4055 Participants
|
|
Family history of early heart and kidney disease
Family history of early kidney disease · Yes
|
266 Participants
n=4055 Participants
|
|
Family history of early heart and kidney disease
Family history of early kidney disease · No
|
2609 Participants
n=4055 Participants
|
|
Family history of early heart and kidney disease
Family history of early kidney disease · Unknown
|
1180 Participants
n=4055 Participants
|
|
10 Years Risk for fatal CVD according to the applying SCORE Risk Chart
|
6.4 scale on a score
STANDARD_DEVIATION 5.5 • n=2613 Participants • Prescribed patient set (PPS): All patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective Type 2 diabetes (T2D) medication and whose documentation was electronically signed by the physician. Only participants with non-missing results are reported.
|
|
Time since diagnosis of type 2 diabetes (T2D)
|
9.9 Years
STANDARD_DEVIATION 6.9 • n=4055 Participants
|
|
Clinical parameter relevant for T2D: HbA1c
|
66.8 millimol/mol
STANDARD_DEVIATION 14.9 • n=3720 Participants • Prescribed patient set (PPS): All patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective T2D medication and whose documentation was electronically signed by the physician. Only participants with non-missing results are reported.
|
|
Clinical parameter relevant for T2D: Glycosylated haemoglobin (HbA1c %)
|
8.3 percentage of glycosylated hemoglobin
STANDARD_DEVIATION 1.4 • n=3720 Participants • Prescribed patient set (PPS): All patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective T2D medication and whose documentation was electronically signed by the physician. Only participants with non-missing results are reported.
|
|
Clinical parameter relevant for T2D: Glycosylated hemoglobin (HbA1c [%])-categorical
<8.5%
|
2477 Participants
n=4055 Participants
|
|
Clinical parameter relevant for T2D: Glycosylated hemoglobin (HbA1c [%])-categorical
≥8.5%
|
1243 Participants
n=4055 Participants
|
|
Clinical parameter relevant for T2D: Glycosylated hemoglobin (HbA1c [%])-categorical
Missing
|
335 Participants
n=4055 Participants
|
|
Prescribed T2D medication
Empagliflozin
|
1966 Participants
n=4055 Participants
|
|
Prescribed T2D medication
Other SGLT2i
|
584 Participants
n=4055 Participants
|
|
Prescribed T2D medication
DPP4i
|
1144 Participants
n=4055 Participants
|
|
Prescribed T2D medication
GLP-1 RA
|
361 Participants
n=4055 Participants
|
|
Prescribed T2D medication
SGLT2i: Canagliflozin
|
156 Participants
n=4055 Participants
|
|
Prescribed T2D medication
SGLT2i: Dapagliflozin
|
425 Participants
n=4055 Participants
|
|
Prescribed T2D medication
SGLT2i: Empagliflozin
|
1966 Participants
n=4055 Participants
|
|
Prescribed T2D medication
SGLT2i: Ertugliflozin
|
3 Participants
n=4055 Participants
|
|
Prescribed T2D medication
DPP4i: Alogliptin
|
94 Participants
n=4055 Participants
|
|
Prescribed T2D medication
DPP4i: Linagliptin
|
457 Participants
n=4055 Participants
|
|
Prescribed T2D medication
DPP4i: Sitagliptin
|
328 Participants
n=4055 Participants
|
|
Prescribed T2D medication
DPP4i: Saxagliptin
|
20 Participants
n=4055 Participants
|
|
Prescribed T2D medication
DPP4i: Vildagliptin
|
245 Participants
n=4055 Participants
|
|
Prescribed T2D medication
GLP-1 RA: Dulaglutide
|
129 Participants
n=4055 Participants
|
|
Prescribed T2D medication
GLP-1 RA: Exenatide
|
16 Participants
n=4055 Participants
|
|
Prescribed T2D medication
GLP-1 RA: Liraglutide
|
165 Participants
n=4055 Participants
|
|
Prescribed T2D medication
GLP-1 RA: Semaglutide
|
2 Participants
n=4055 Participants
|
|
Prescribed T2D medication
GLP-1 RA: Lixisenatide
|
49 Participants
n=4055 Participants
|
PRIMARY outcome
Timeframe: At study index date 1 (i.e. between September 2018 and December 2018).Population: Prescribed patient set (PPS): All patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective T2D medication and whose documentation was electronically signed by the physician.
Number of patients in each category of prescription of a respective modern Type 2 Diabetes (T2D) medication according to prescribing specialist is reported.
Outcome measures
| Measure |
Patients Initiated on T2D Medication by Endocrinologist
n=1652 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by endocrinologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Diabetologist
n=2301 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by diabetologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Cardiologist
n=102 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by cardiologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on Other SGLT2i by Endocrinologist
Patients with type 2 diabetes from Central Eastern Europe (CEE) (i.e. Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who have been newly initiated (first ever use) on other sodium dependent glucose transporter inhibitor (SGLT2i) between September 2018 and December 2018 (study index date 1) by endocrinologist.
|
T2D Patients From Russian Federation
Patients with type 2 diabetes (T2D) from Russian Federation who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) between September 2018 and December 2018 (study index date 1) and have consented to documentation at study index date 2.
|
|---|---|---|---|---|---|
|
Number of Patients in Each Category of First Prescription of a Respective Modern Type 2 Diabetes (T2D) Medication According to Prescribing Specialist
Empagliflozin
|
815 Participants
|
1073 Participants
|
78 Participants
|
—
|
—
|
|
Number of Patients in Each Category of First Prescription of a Respective Modern Type 2 Diabetes (T2D) Medication According to Prescribing Specialist
Other SGLT2i
|
244 Participants
|
333 Participants
|
7 Participants
|
—
|
—
|
|
Number of Patients in Each Category of First Prescription of a Respective Modern Type 2 Diabetes (T2D) Medication According to Prescribing Specialist
DPP4i
|
504 Participants
|
624 Participants
|
16 Participants
|
—
|
—
|
|
Number of Patients in Each Category of First Prescription of a Respective Modern Type 2 Diabetes (T2D) Medication According to Prescribing Specialist
GLP-1 RA
|
89 Participants
|
271 Participants
|
1 Participants
|
—
|
—
|
PRIMARY outcome
Timeframe: At study index date 1 (i.e. between September 2018 and December 2018).Population: Prescribed patient set (PPS): All patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective T2D medication and whose documentation was electronically signed by the physician.
Number of patients initiated on a modern type 2 diabetes (T2D) medication who also received concomitant T2D medications at study index date 1 according to prescribing specialist is reported. The concomitant T2D medications reported are: * Metformin * Sulfonylurea * Acarbose * Pioglitazone * Insulin * Others
Outcome measures
| Measure |
Patients Initiated on T2D Medication by Endocrinologist
n=1652 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by endocrinologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Diabetologist
n=2301 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by diabetologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Cardiologist
n=102 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by cardiologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on Other SGLT2i by Endocrinologist
Patients with type 2 diabetes from Central Eastern Europe (CEE) (i.e. Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who have been newly initiated (first ever use) on other sodium dependent glucose transporter inhibitor (SGLT2i) between September 2018 and December 2018 (study index date 1) by endocrinologist.
|
T2D Patients From Russian Federation
Patients with type 2 diabetes (T2D) from Russian Federation who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) between September 2018 and December 2018 (study index date 1) and have consented to documentation at study index date 2.
|
|---|---|---|---|---|---|
|
Number of Patients Initiated on a Modern Type 2 Diabetes (T2D) Medication Who Also Received Concomitant T2D Medications at Study Index Date 1 According to Prescribing Specialist
Metformin
|
1349 Participants
|
1794 Participants
|
81 Participants
|
—
|
—
|
|
Number of Patients Initiated on a Modern Type 2 Diabetes (T2D) Medication Who Also Received Concomitant T2D Medications at Study Index Date 1 According to Prescribing Specialist
Sulfonylurea
|
626 Participants
|
513 Participants
|
17 Participants
|
—
|
—
|
|
Number of Patients Initiated on a Modern Type 2 Diabetes (T2D) Medication Who Also Received Concomitant T2D Medications at Study Index Date 1 According to Prescribing Specialist
Acarbose
|
3 Participants
|
49 Participants
|
3 Participants
|
—
|
—
|
|
Number of Patients Initiated on a Modern Type 2 Diabetes (T2D) Medication Who Also Received Concomitant T2D Medications at Study Index Date 1 According to Prescribing Specialist
Pioglitazone
|
3 Participants
|
91 Participants
|
0 Participants
|
—
|
—
|
|
Number of Patients Initiated on a Modern Type 2 Diabetes (T2D) Medication Who Also Received Concomitant T2D Medications at Study Index Date 1 According to Prescribing Specialist
Insulin
|
342 Participants
|
658 Participants
|
17 Participants
|
—
|
—
|
|
Number of Patients Initiated on a Modern Type 2 Diabetes (T2D) Medication Who Also Received Concomitant T2D Medications at Study Index Date 1 According to Prescribing Specialist
Others
|
59 Participants
|
91 Participants
|
7 Participants
|
—
|
—
|
PRIMARY outcome
Timeframe: At study index date 1 (i.e. between September 2018 and December 2018).Population: Prescribed patient set (PPS): All patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective T2D medication and whose documentation was electronically signed by the physician.
Number of patients initiated on a modern type 2 diabetes (T2D) medication who also received concomitant cardiovascular disease (CVD) and/or chronic kidney disease (CKD) medication at study index date 1 according to prescribing specialist is reported. The reported concomitant CVD and/or chronic CKD medications are: * Antihypertensive angiotensin-converting-enzyme inhibitors (ACEi) or angiotensin II receptor blockers (ARBs) * Statins * Low dose aspirin * Beta blockers * Diuretics * Others
Outcome measures
| Measure |
Patients Initiated on T2D Medication by Endocrinologist
n=1652 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by endocrinologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Diabetologist
n=2301 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by diabetologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Cardiologist
n=102 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by cardiologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on Other SGLT2i by Endocrinologist
Patients with type 2 diabetes from Central Eastern Europe (CEE) (i.e. Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who have been newly initiated (first ever use) on other sodium dependent glucose transporter inhibitor (SGLT2i) between September 2018 and December 2018 (study index date 1) by endocrinologist.
|
T2D Patients From Russian Federation
Patients with type 2 diabetes (T2D) from Russian Federation who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) between September 2018 and December 2018 (study index date 1) and have consented to documentation at study index date 2.
|
|---|---|---|---|---|---|
|
Number of Patients Initiated on a Modern Type 2 Diabetes (T2D) Medication Who Also Received Concomitant Cardiovascular Disease (CVD) and/or Chronic Kidney Disease (CKD) Medication at Study Index Date 1 According to Prescribing Specialist
Beta blockers
|
580 Participants
|
922 Participants
|
73 Participants
|
—
|
—
|
|
Number of Patients Initiated on a Modern Type 2 Diabetes (T2D) Medication Who Also Received Concomitant Cardiovascular Disease (CVD) and/or Chronic Kidney Disease (CKD) Medication at Study Index Date 1 According to Prescribing Specialist
Diuretics
|
471 Participants
|
732 Participants
|
44 Participants
|
—
|
—
|
|
Number of Patients Initiated on a Modern Type 2 Diabetes (T2D) Medication Who Also Received Concomitant Cardiovascular Disease (CVD) and/or Chronic Kidney Disease (CKD) Medication at Study Index Date 1 According to Prescribing Specialist
Others
|
160 Participants
|
455 Participants
|
29 Participants
|
—
|
—
|
|
Number of Patients Initiated on a Modern Type 2 Diabetes (T2D) Medication Who Also Received Concomitant Cardiovascular Disease (CVD) and/or Chronic Kidney Disease (CKD) Medication at Study Index Date 1 According to Prescribing Specialist
Antihypertensive ACEi or ARBs
|
1256 Participants
|
1536 Participants
|
87 Participants
|
—
|
—
|
|
Number of Patients Initiated on a Modern Type 2 Diabetes (T2D) Medication Who Also Received Concomitant Cardiovascular Disease (CVD) and/or Chronic Kidney Disease (CKD) Medication at Study Index Date 1 According to Prescribing Specialist
Statins
|
983 Participants
|
1327 Participants
|
82 Participants
|
—
|
—
|
|
Number of Patients Initiated on a Modern Type 2 Diabetes (T2D) Medication Who Also Received Concomitant Cardiovascular Disease (CVD) and/or Chronic Kidney Disease (CKD) Medication at Study Index Date 1 According to Prescribing Specialist
Low dose aspirin
|
555 Participants
|
622 Participants
|
64 Participants
|
—
|
—
|
PRIMARY outcome
Timeframe: At study index date 1 (i.e. between September 2018 and December 2018).Population: Patients of the prescribed patient set (PPS) who were initiated on type 2 diabetes (T2D) medication by endocrinologist. PPS included all patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective T2D medication and whose documentation was electronically signed by the physician.
Baseline characteristic: Age according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by endocrinologist is reported. Age for each patient was calculated by subtracting the year of birth from the year of registration (i.e. Year of registration - Year of birth). Year of registration was defined as the year the patients where initiated on T2D medication.
Outcome measures
| Measure |
Patients Initiated on T2D Medication by Endocrinologist
n=815 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by endocrinologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Diabetologist
n=504 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by diabetologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Cardiologist
n=89 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by cardiologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on Other SGLT2i by Endocrinologist
n=244 Participants
Patients with type 2 diabetes from Central Eastern Europe (CEE) (i.e. Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who have been newly initiated (first ever use) on other sodium dependent glucose transporter inhibitor (SGLT2i) between September 2018 and December 2018 (study index date 1) by endocrinologist.
|
T2D Patients From Russian Federation
Patients with type 2 diabetes (T2D) from Russian Federation who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) between September 2018 and December 2018 (study index date 1) and have consented to documentation at study index date 2.
|
|---|---|---|---|---|---|
|
Baseline Characteristic: Age According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist
|
61.5 Years
Standard Deviation 9.7
|
65.3 Years
Standard Deviation 10.4
|
55.8 Years
Standard Deviation 10.5
|
62.0 Years
Standard Deviation 9.2
|
—
|
PRIMARY outcome
Timeframe: At study index date 1 (i.e. between September 2018 and December 2018).Population: Patients of the prescribed patient set (PPS) who were initiated on type 2 diabetes (T2D) medication by endocrinologist. PPS included all patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective T2D medication and whose documentation was electronically signed by the physician.
Baseline characteristic: Number of patients in each category of gender according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by endocrinologist is reported. The reported categories of gender are: * Female * Male
Outcome measures
| Measure |
Patients Initiated on T2D Medication by Endocrinologist
n=815 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by endocrinologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Diabetologist
n=504 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by diabetologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Cardiologist
n=89 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by cardiologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on Other SGLT2i by Endocrinologist
n=244 Participants
Patients with type 2 diabetes from Central Eastern Europe (CEE) (i.e. Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who have been newly initiated (first ever use) on other sodium dependent glucose transporter inhibitor (SGLT2i) between September 2018 and December 2018 (study index date 1) by endocrinologist.
|
T2D Patients From Russian Federation
Patients with type 2 diabetes (T2D) from Russian Federation who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) between September 2018 and December 2018 (study index date 1) and have consented to documentation at study index date 2.
|
|---|---|---|---|---|---|
|
Baseline Characteristic: Number of Patients in Each Category of Gender According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist
Female
|
432 Participants
|
334 Participants
|
37 Participants
|
140 Participants
|
—
|
|
Baseline Characteristic: Number of Patients in Each Category of Gender According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist
Male
|
383 Participants
|
170 Participants
|
52 Participants
|
104 Participants
|
—
|
PRIMARY outcome
Timeframe: At study index date 1 (i.e. between September 2018 and December 2018).Population: Patients of the prescribed patient set (PPS) who were initiated on type 2 diabetes (T2D) medication by endocrinologist. PPS included all patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective T2D medication and whose documentation was electronically signed by the physician.
Baseline characteristic: Body mass index (BMI) according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by endocrinologist is reported. Body mass index (BMI) is weight in kilograms divided by height in meters squared (kilogram/meter\^2 (kg/m\^2)).
Outcome measures
| Measure |
Patients Initiated on T2D Medication by Endocrinologist
n=815 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by endocrinologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Diabetologist
n=504 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by diabetologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Cardiologist
n=89 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by cardiologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on Other SGLT2i by Endocrinologist
n=244 Participants
Patients with type 2 diabetes from Central Eastern Europe (CEE) (i.e. Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who have been newly initiated (first ever use) on other sodium dependent glucose transporter inhibitor (SGLT2i) between September 2018 and December 2018 (study index date 1) by endocrinologist.
|
T2D Patients From Russian Federation
Patients with type 2 diabetes (T2D) from Russian Federation who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) between September 2018 and December 2018 (study index date 1) and have consented to documentation at study index date 2.
|
|---|---|---|---|---|---|
|
Baseline Characteristic: Body Mass Index (BMI) According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist
|
33.3 kilogram/meter^2 (kg/m^2)
Standard Deviation 5.4
|
31.3 kilogram/meter^2 (kg/m^2)
Standard Deviation 5.2
|
36.7 kilogram/meter^2 (kg/m^2)
Standard Deviation 5.9
|
34.3 kilogram/meter^2 (kg/m^2)
Standard Deviation 5.8
|
—
|
PRIMARY outcome
Timeframe: At study index date 1 (i.e. between September 2018 and December 2018).Population: Patients of the prescribed patient set (PPS) who were initiated on type 2 diabetes (T2D) medication by endocrinologist. PPS included all patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective T2D medication and whose documentation was electronically signed by the physician.
Baseline characteristic: Number of patients in each category of race according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by endocrinologist is reported. The reported categories of race are: * Black * Non-black
Outcome measures
| Measure |
Patients Initiated on T2D Medication by Endocrinologist
n=815 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by endocrinologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Diabetologist
n=504 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by diabetologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Cardiologist
n=89 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by cardiologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on Other SGLT2i by Endocrinologist
n=244 Participants
Patients with type 2 diabetes from Central Eastern Europe (CEE) (i.e. Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who have been newly initiated (first ever use) on other sodium dependent glucose transporter inhibitor (SGLT2i) between September 2018 and December 2018 (study index date 1) by endocrinologist.
|
T2D Patients From Russian Federation
Patients with type 2 diabetes (T2D) from Russian Federation who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) between September 2018 and December 2018 (study index date 1) and have consented to documentation at study index date 2.
|
|---|---|---|---|---|---|
|
Baseline Characteristic: Number of Patients in Each Category of Race According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist
Black
|
10 Participants
|
7 Participants
|
1 Participants
|
5 Participants
|
—
|
|
Baseline Characteristic: Number of Patients in Each Category of Race According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist
Non-black
|
805 Participants
|
497 Participants
|
88 Participants
|
239 Participants
|
—
|
PRIMARY outcome
Timeframe: At study index date 1 (i.e. between September 2018 and December 2018).Population: Patients of the prescribed patient set (PPS) who were initiated on type 2 diabetes (T2D) medication by diabetologist. PPS included all patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective T2D medication and whose documentation was electronically signed by the physician.
Baseline characteristic: Age according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by diabetologist is reported. Age for each patient was calculated by subtracting the year of birth from the year of registration (i.e. Year of registration - Year of birth). Year of registration was defined as the year the patients where initiated on T2D medication.
Outcome measures
| Measure |
Patients Initiated on T2D Medication by Endocrinologist
n=1073 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by endocrinologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Diabetologist
n=624 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by diabetologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Cardiologist
n=271 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by cardiologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on Other SGLT2i by Endocrinologist
n=333 Participants
Patients with type 2 diabetes from Central Eastern Europe (CEE) (i.e. Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who have been newly initiated (first ever use) on other sodium dependent glucose transporter inhibitor (SGLT2i) between September 2018 and December 2018 (study index date 1) by endocrinologist.
|
T2D Patients From Russian Federation
Patients with type 2 diabetes (T2D) from Russian Federation who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) between September 2018 and December 2018 (study index date 1) and have consented to documentation at study index date 2.
|
|---|---|---|---|---|---|
|
Baseline Characteristic: Age According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist
|
63.0 Years
Standard Deviation 9.4
|
67.2 Years
Standard Deviation 11.0
|
59.2 Years
Standard Deviation 10.8
|
62.3 Years
Standard Deviation 9.2
|
—
|
PRIMARY outcome
Timeframe: At study index date 1 (i.e. between September 2018 and December 2018).Population: Patients of the prescribed patient set (PPS) who were initiated on type 2 diabetes (T2D) medication by diabetologist. PPS included all patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective T2D medication and whose documentation was electronically signed by the physician.
Baseline characteristic: Number of patients in each category of gender according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by diabetologist is reported. The reported categories of gender are: * Female * Male
Outcome measures
| Measure |
Patients Initiated on T2D Medication by Endocrinologist
n=1073 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by endocrinologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Diabetologist
n=624 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by diabetologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Cardiologist
n=271 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by cardiologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on Other SGLT2i by Endocrinologist
n=333 Participants
Patients with type 2 diabetes from Central Eastern Europe (CEE) (i.e. Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who have been newly initiated (first ever use) on other sodium dependent glucose transporter inhibitor (SGLT2i) between September 2018 and December 2018 (study index date 1) by endocrinologist.
|
T2D Patients From Russian Federation
Patients with type 2 diabetes (T2D) from Russian Federation who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) between September 2018 and December 2018 (study index date 1) and have consented to documentation at study index date 2.
|
|---|---|---|---|---|---|
|
Baseline Characteristic: Number of Patients in Each Category of Gender According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist
Female
|
433 Participants
|
297 Participants
|
135 Participants
|
140 Participants
|
—
|
|
Baseline Characteristic: Number of Patients in Each Category of Gender According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist
Male
|
640 Participants
|
327 Participants
|
136 Participants
|
193 Participants
|
—
|
PRIMARY outcome
Timeframe: At study index date 1 (i.e. between September 2018 and December 2018).Population: Patients of the prescribed patient set (PPS) who were initiated on type 2 diabetes (T2D) medication by diabetologist. PPS included all patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective T2D medication and whose documentation was electronically signed by the physician.
Baseline characteristic: Body mass index (BMI) according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by diabetologist is reported. Body mass index (BMI) is weight in kilograms divided by height in meters squared (kilogram/meter\^2 (kg/m\^2)).
Outcome measures
| Measure |
Patients Initiated on T2D Medication by Endocrinologist
n=1073 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by endocrinologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Diabetologist
n=624 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by diabetologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Cardiologist
n=271 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by cardiologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on Other SGLT2i by Endocrinologist
n=333 Participants
Patients with type 2 diabetes from Central Eastern Europe (CEE) (i.e. Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who have been newly initiated (first ever use) on other sodium dependent glucose transporter inhibitor (SGLT2i) between September 2018 and December 2018 (study index date 1) by endocrinologist.
|
T2D Patients From Russian Federation
Patients with type 2 diabetes (T2D) from Russian Federation who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) between September 2018 and December 2018 (study index date 1) and have consented to documentation at study index date 2.
|
|---|---|---|---|---|---|
|
Body Mass Index (BMI) According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist
|
33.3 kilogram/meter^2 (kg/m^2)
Standard Deviation 5.9
|
31.0 kilogram/meter^2 (kg/m^2)
Standard Deviation 5.4
|
36.2 kilogram/meter^2 (kg/m^2)
Standard Deviation 6.7
|
32.8 kilogram/meter^2 (kg/m^2)
Standard Deviation 5.3
|
—
|
PRIMARY outcome
Timeframe: At study index date 1 (i.e. between September 2018 and December 2018).Population: Patients of the prescribed patient set (PPS) who were initiated on type 2 diabetes (T2D) medication by diabetologist. PPS included all patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective T2D medication and whose documentation was electronically signed by the physician.
Baseline characteristic: Number of patients in each category of race according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by diabetologist is reported. The reported categories of race are: * Black * Non-black
Outcome measures
| Measure |
Patients Initiated on T2D Medication by Endocrinologist
n=1073 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by endocrinologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Diabetologist
n=624 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by diabetologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Cardiologist
n=271 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by cardiologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on Other SGLT2i by Endocrinologist
n=333 Participants
Patients with type 2 diabetes from Central Eastern Europe (CEE) (i.e. Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who have been newly initiated (first ever use) on other sodium dependent glucose transporter inhibitor (SGLT2i) between September 2018 and December 2018 (study index date 1) by endocrinologist.
|
T2D Patients From Russian Federation
Patients with type 2 diabetes (T2D) from Russian Federation who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) between September 2018 and December 2018 (study index date 1) and have consented to documentation at study index date 2.
|
|---|---|---|---|---|---|
|
Baseline Characteristic: Number of Patients in Each Category of Race According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist
Black
|
3 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
—
|
|
Baseline Characteristic: Number of Patients in Each Category of Race According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist
Non-black
|
1070 Participants
|
624 Participants
|
270 Participants
|
333 Participants
|
—
|
PRIMARY outcome
Timeframe: At study index date 1 (i.e. between September 2018 and December 2018).Population: Patients of the prescribed patient set (PPS) who were initiated on type 2 diabetes (T2D) medication by cardiologist. PPS included all patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective T2D medication and whose documentation was electronically signed by the physician.
Baseline characteristic: Age according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by cardiologist is reported. Age for each patient was calculated by subtracting the year of birth from the year of registration (i.e. Year of registration - Year of birth). Year of registration was defined as the year the patients where initiated on T2D medication.
Outcome measures
| Measure |
Patients Initiated on T2D Medication by Endocrinologist
n=78 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by endocrinologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Diabetologist
n=16 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by diabetologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Cardiologist
n=1 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by cardiologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on Other SGLT2i by Endocrinologist
n=7 Participants
Patients with type 2 diabetes from Central Eastern Europe (CEE) (i.e. Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who have been newly initiated (first ever use) on other sodium dependent glucose transporter inhibitor (SGLT2i) between September 2018 and December 2018 (study index date 1) by endocrinologist.
|
T2D Patients From Russian Federation
Patients with type 2 diabetes (T2D) from Russian Federation who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) between September 2018 and December 2018 (study index date 1) and have consented to documentation at study index date 2.
|
|---|---|---|---|---|---|
|
Baseline Characteristic: Age According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist
|
64.4 Years
Standard Deviation 8.4
|
70.9 Years
Standard Deviation 9.5
|
54.0 Years
|
65.0 Years
Standard Deviation 9.4
|
—
|
PRIMARY outcome
Timeframe: At study index date 1 (i.e. between September 2018 and December 2018).Population: Patients of the prescribed patient set (PPS) who were initiated on type 2 diabetes (T2D) medication by cardiologist. PPS included all patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective T2D medication and whose documentation was electronically signed by the physician.
Baseline characteristic: Number of patients in each category of gender according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by cardiologist is reported. The reported categories of gender are: * Female * Male
Outcome measures
| Measure |
Patients Initiated on T2D Medication by Endocrinologist
n=78 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by endocrinologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Diabetologist
n=16 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by diabetologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Cardiologist
n=1 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by cardiologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on Other SGLT2i by Endocrinologist
n=7 Participants
Patients with type 2 diabetes from Central Eastern Europe (CEE) (i.e. Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who have been newly initiated (first ever use) on other sodium dependent glucose transporter inhibitor (SGLT2i) between September 2018 and December 2018 (study index date 1) by endocrinologist.
|
T2D Patients From Russian Federation
Patients with type 2 diabetes (T2D) from Russian Federation who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) between September 2018 and December 2018 (study index date 1) and have consented to documentation at study index date 2.
|
|---|---|---|---|---|---|
|
Baseline Characteristic: Number of Patients in Each Category of Gender According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist
Female
|
35 Participants
|
8 Participants
|
0 Participants
|
2 Participants
|
—
|
|
Baseline Characteristic: Number of Patients in Each Category of Gender According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist
Male
|
43 Participants
|
8 Participants
|
1 Participants
|
5 Participants
|
—
|
PRIMARY outcome
Timeframe: At study index date 1 (i.e. between September 2018 and December 2018).Population: Patients of the prescribed patient set (PPS) who were initiated on type 2 diabetes (T2D) medication by cardiologist. PPS included all patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective T2D medication and whose documentation was electronically signed by the physician.
Baseline characteristic: Body mass index (BMI) according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by cardiologist is reported. Body mass index (BMI) is weight in kilograms divided by height in meters squared (kilogram/meter\^2 (kg/m\^2)).
Outcome measures
| Measure |
Patients Initiated on T2D Medication by Endocrinologist
n=78 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by endocrinologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Diabetologist
n=16 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by diabetologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Cardiologist
n=1 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by cardiologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on Other SGLT2i by Endocrinologist
n=7 Participants
Patients with type 2 diabetes from Central Eastern Europe (CEE) (i.e. Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who have been newly initiated (first ever use) on other sodium dependent glucose transporter inhibitor (SGLT2i) between September 2018 and December 2018 (study index date 1) by endocrinologist.
|
T2D Patients From Russian Federation
Patients with type 2 diabetes (T2D) from Russian Federation who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) between September 2018 and December 2018 (study index date 1) and have consented to documentation at study index date 2.
|
|---|---|---|---|---|---|
|
Body Mass Index (BMI) According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist
|
30.8 kilogram/meter^2 (kg/m^2)
Standard Deviation 4.6
|
29.9 kilogram/meter^2 (kg/m^2)
Standard Deviation 4.2
|
25.8 kilogram/meter^2 (kg/m^2)
|
30.7 kilogram/meter^2 (kg/m^2)
Standard Deviation 2.3
|
—
|
PRIMARY outcome
Timeframe: At study index date 1 (i.e. between September 2018 and December 2018).Population: Patients of the prescribed patient set (PPS) who were initiated on type 2 diabetes (T2D) medication by cardiologist. PPS included all patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective T2D medication and whose documentation was electronically signed by the physician.
Baseline characteristic: Number of patients in each category of race according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by cardiologist is reported. The reported categories of race are: * Black * Non-black
Outcome measures
| Measure |
Patients Initiated on T2D Medication by Endocrinologist
n=78 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by endocrinologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Diabetologist
n=16 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by diabetologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Cardiologist
n=1 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by cardiologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on Other SGLT2i by Endocrinologist
n=7 Participants
Patients with type 2 diabetes from Central Eastern Europe (CEE) (i.e. Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who have been newly initiated (first ever use) on other sodium dependent glucose transporter inhibitor (SGLT2i) between September 2018 and December 2018 (study index date 1) by endocrinologist.
|
T2D Patients From Russian Federation
Patients with type 2 diabetes (T2D) from Russian Federation who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) between September 2018 and December 2018 (study index date 1) and have consented to documentation at study index date 2.
|
|---|---|---|---|---|---|
|
Baseline Characteristic: Number of Patients in Each Category of Race According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist
Black
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
—
|
|
Baseline Characteristic: Number of Patients in Each Category of Race According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist
Non-black
|
78 Participants
|
16 Participants
|
1 Participants
|
7 Participants
|
—
|
PRIMARY outcome
Timeframe: At study index date 1 (i.e. between September 2018 and December 2018).Population: Patients of the prescribed patient set (PPS) who were initiated on type 2 diabetes (T2D) medication by endocrinologist. PPS included all patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective T2D medication and whose documentation was electronically signed by the physician.
Time since diagnosis of type 2 diabetes (T2D) according to T2D medication for the patients who were initiated on T2D medication by endocrinologist is reported. Time since diagnosis of T2D (years) was calculated by subtracting the year of T2D diagnosis from the year of registration. Year of registration was defined as the year patients where initiated on T2D medication.
Outcome measures
| Measure |
Patients Initiated on T2D Medication by Endocrinologist
n=815 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by endocrinologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Diabetologist
n=504 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by diabetologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Cardiologist
n=89 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by cardiologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on Other SGLT2i by Endocrinologist
n=244 Participants
Patients with type 2 diabetes from Central Eastern Europe (CEE) (i.e. Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who have been newly initiated (first ever use) on other sodium dependent glucose transporter inhibitor (SGLT2i) between September 2018 and December 2018 (study index date 1) by endocrinologist.
|
T2D Patients From Russian Federation
Patients with type 2 diabetes (T2D) from Russian Federation who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) between September 2018 and December 2018 (study index date 1) and have consented to documentation at study index date 2.
|
|---|---|---|---|---|---|
|
Time Since Diagnosis of Type 2 Diabetes (T2D) According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist
|
9.1 Years
Standard Deviation 6.6
|
9.1 Years
Standard Deviation 6.6
|
9.2 Years
Standard Deviation 6.9
|
9.8 Years
Standard Deviation 6.7
|
—
|
PRIMARY outcome
Timeframe: At study index date 1 (i.e. between September 2018 and December 2018).Population: Patients of the prescribed patient set (PPS) who were initiated on type 2 diabetes (T2D) medication by diabetologist. PPS included all patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective T2D medication and whose documentation was electronically signed by the physician.
Time since diagnosis of type 2 diabetes (T2D) according to T2D medication for the patients who were initiated on T2D medication by diabetologist is reported. Time since diagnosis of T2D (years) was calculated by subtracting the year of T2D diagnosis from the year of registration. Year of registration was defined as the year patients where initiated on T2D medication.
Outcome measures
| Measure |
Patients Initiated on T2D Medication by Endocrinologist
n=1073 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by endocrinologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Diabetologist
n=624 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by diabetologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Cardiologist
n=271 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by cardiologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on Other SGLT2i by Endocrinologist
n=333 Participants
Patients with type 2 diabetes from Central Eastern Europe (CEE) (i.e. Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who have been newly initiated (first ever use) on other sodium dependent glucose transporter inhibitor (SGLT2i) between September 2018 and December 2018 (study index date 1) by endocrinologist.
|
T2D Patients From Russian Federation
Patients with type 2 diabetes (T2D) from Russian Federation who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) between September 2018 and December 2018 (study index date 1) and have consented to documentation at study index date 2.
|
|---|---|---|---|---|---|
|
Time Since Diagnosis of Type 2 Diabetes (T2D) According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist
|
10.7 Years
Standard Deviation 7.3
|
10.4 Years
Standard Deviation 7.3
|
10.1 Years
Standard Deviation 6.6
|
10.1 Years
Standard Deviation 6.8
|
—
|
PRIMARY outcome
Timeframe: At study index date 1 (i.e. between September 2018 and December 2018).Population: Patients of the prescribed patient set (PPS) who were initiated on type 2 diabetes (T2D) medication by cardiologist. PPS included all patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective T2D medication and whose documentation was electronically signed by the physician.
Time since diagnosis of type 2 diabetes (T2D) according to T2D medication for the patients who were initiated on T2D medication by cardiologist is reported. Time since diagnosis of T2D (years) was calculated by subtracting the year of T2D diagnosis from the year of registration. Year of registration was defined as the year patients where initiated on T2D medication.
Outcome measures
| Measure |
Patients Initiated on T2D Medication by Endocrinologist
n=78 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by endocrinologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Diabetologist
n=16 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by diabetologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Cardiologist
n=1 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by cardiologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on Other SGLT2i by Endocrinologist
n=7 Participants
Patients with type 2 diabetes from Central Eastern Europe (CEE) (i.e. Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who have been newly initiated (first ever use) on other sodium dependent glucose transporter inhibitor (SGLT2i) between September 2018 and December 2018 (study index date 1) by endocrinologist.
|
T2D Patients From Russian Federation
Patients with type 2 diabetes (T2D) from Russian Federation who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) between September 2018 and December 2018 (study index date 1) and have consented to documentation at study index date 2.
|
|---|---|---|---|---|---|
|
Time Since Diagnosis of Type 2 Diabetes (T2D) According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist
|
6.7 Years
Standard Deviation 4.0
|
9.7 Years
Standard Deviation 5.7
|
6.0 Years
|
10.9 Years
Standard Deviation 6.5
|
—
|
PRIMARY outcome
Timeframe: At study index date 1 (i.e. between September 2018 and December 2018).Population: Patients of the prescribed patient set (PPS) who were initiated on type 2 diabetes (T2D) medication by endocrinologist. PPS included all patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective T2D medication and whose documentation was electronically signed by the physician. Only participants with non-missing results are reported.
Clinical parameter relevant for Type 2 Diabetes (T2D): Percentage of glycosylated hemoglobin (HbA1c \[%\]) according to T2D medication for the patients who were initiated on T2D medication by endocrinologist is reported.
Outcome measures
| Measure |
Patients Initiated on T2D Medication by Endocrinologist
n=802 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by endocrinologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Diabetologist
n=477 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by diabetologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Cardiologist
n=85 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by cardiologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on Other SGLT2i by Endocrinologist
n=235 Participants
Patients with type 2 diabetes from Central Eastern Europe (CEE) (i.e. Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who have been newly initiated (first ever use) on other sodium dependent glucose transporter inhibitor (SGLT2i) between September 2018 and December 2018 (study index date 1) by endocrinologist.
|
T2D Patients From Russian Federation
Patients with type 2 diabetes (T2D) from Russian Federation who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) between September 2018 and December 2018 (study index date 1) and have consented to documentation at study index date 2.
|
|---|---|---|---|---|---|
|
Clinical Parameter Relevant for Type 2 Diabetes (T2D): Percentage of Glycosylated Hemoglobin (HbA1c [%]) According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist
|
8.5 percentage of glycosylated hemoglobin
Standard Deviation 1.4
|
8.1 percentage of glycosylated hemoglobin
Standard Deviation 1.2
|
8.2 percentage of glycosylated hemoglobin
Standard Deviation 1.1
|
8.5 percentage of glycosylated hemoglobin
Standard Deviation 1.3
|
—
|
PRIMARY outcome
Timeframe: At study index date 1 (i.e. between September 2018 and December 2018).Population: Patients of the prescribed patient set (PPS) who were initiated on type 2 diabetes (T2D) medication by endocrinologist. PPS included all patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective T2D medication and whose documentation was electronically signed by the physician.
Clinical parameter relevant for Type 2 Diabetes (T2D): Number of patients in each category of percentage of glycosylated hemoglobin (HbA1c) according to T2D medication for the patients who were initiated on T2D medication by endocrinologist is reported. The reported categories of percentage (%) of glycosylated hemoglobin are: * \<8.5% * ≥8.5% * Missing
Outcome measures
| Measure |
Patients Initiated on T2D Medication by Endocrinologist
n=815 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by endocrinologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Diabetologist
n=504 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by diabetologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Cardiologist
n=89 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by cardiologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on Other SGLT2i by Endocrinologist
n=244 Participants
Patients with type 2 diabetes from Central Eastern Europe (CEE) (i.e. Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who have been newly initiated (first ever use) on other sodium dependent glucose transporter inhibitor (SGLT2i) between September 2018 and December 2018 (study index date 1) by endocrinologist.
|
T2D Patients From Russian Federation
Patients with type 2 diabetes (T2D) from Russian Federation who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) between September 2018 and December 2018 (study index date 1) and have consented to documentation at study index date 2.
|
|---|---|---|---|---|---|
|
Clinical Parameter Relevant for T2D: Number of Patients in Each Category of Percentage of Glycosylated Hemoglobin (HbA1c) According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist
<8.5%
|
453 Participants
|
339 Participants
|
56 Participants
|
138 Participants
|
—
|
|
Clinical Parameter Relevant for T2D: Number of Patients in Each Category of Percentage of Glycosylated Hemoglobin (HbA1c) According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist
≥8.5%
|
349 Participants
|
138 Participants
|
29 Participants
|
97 Participants
|
—
|
|
Clinical Parameter Relevant for T2D: Number of Patients in Each Category of Percentage of Glycosylated Hemoglobin (HbA1c) According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist
Missing
|
13 Participants
|
27 Participants
|
4 Participants
|
9 Participants
|
—
|
PRIMARY outcome
Timeframe: At study index date 1 (i.e. between September 2018 and December 2018).Population: Patients of the prescribed patient set (PPS) who were initiated on type by diabetologist. PPS included all patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective T2D medication and whose documentation was electronically signed by the physician. Only participants with non-missing results are reported.
Clinical parameter relevant for type 2 diabetes (T2D): Percentage of glycosylated hemoglobin (HbA1c \[%\]) according to T2D medication for the patients who were initiated on T2D medication by diabetologist is reported.
Outcome measures
| Measure |
Patients Initiated on T2D Medication by Endocrinologist
n=920 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by endocrinologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Diabetologist
n=576 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by diabetologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Cardiologist
n=257 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by cardiologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on Other SGLT2i by Endocrinologist
n=297 Participants
Patients with type 2 diabetes from Central Eastern Europe (CEE) (i.e. Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who have been newly initiated (first ever use) on other sodium dependent glucose transporter inhibitor (SGLT2i) between September 2018 and December 2018 (study index date 1) by endocrinologist.
|
T2D Patients From Russian Federation
Patients with type 2 diabetes (T2D) from Russian Federation who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) between September 2018 and December 2018 (study index date 1) and have consented to documentation at study index date 2.
|
|---|---|---|---|---|---|
|
Clinical Parameter Relevant for Type 2 Diabetes (T2D): Percentage of Glycosylated Hemoglobin (HbA1c [%]) According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist
|
8.2 percentage of glycosylated hemoglobin
Standard Deviation 1.3
|
7.9 percentage of glycosylated hemoglobin
Standard Deviation 1.4
|
8.4 percentage of glycosylated hemoglobin
Standard Deviation 1.2
|
8.6 percentage of glycosylated hemoglobin
Standard Deviation 1.6
|
—
|
PRIMARY outcome
Timeframe: At study index date 1 (i.e. between September 2018 and December 2018).Population: Patients of the prescribed patient set (PPS) who were initiated on type 2 diabetes (T2D) medication by diabetologist. PPS included all patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective T2D medication and whose documentation was electronically signed by the physician.
Clinical parameter relevant for type 2 diabetes (T2D): Number of patients in each category of percentage of glycosylated hemoglobin (HbA1c) according to T2D medication for the patients who were initiated on T2D medication by diabetologist is reported. The reported categories of percentage of glycosylated hemoglobin are: * \<8.5% * ≥8.5% * Missing
Outcome measures
| Measure |
Patients Initiated on T2D Medication by Endocrinologist
n=1073 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by endocrinologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Diabetologist
n=624 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by diabetologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Cardiologist
n=271 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by cardiologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on Other SGLT2i by Endocrinologist
n=333 Participants
Patients with type 2 diabetes from Central Eastern Europe (CEE) (i.e. Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who have been newly initiated (first ever use) on other sodium dependent glucose transporter inhibitor (SGLT2i) between September 2018 and December 2018 (study index date 1) by endocrinologist.
|
T2D Patients From Russian Federation
Patients with type 2 diabetes (T2D) from Russian Federation who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) between September 2018 and December 2018 (study index date 1) and have consented to documentation at study index date 2.
|
|---|---|---|---|---|---|
|
Clinical Parameter Relevant for Type 2 Diabetes (T2D): Number of Patients in Each Category of Percentage of Glycosylated Hemoglobin (HbA1c) According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist
<8.5%
|
642 Participants
|
453 Participants
|
162 Participants
|
183 Participants
|
—
|
|
Clinical Parameter Relevant for Type 2 Diabetes (T2D): Number of Patients in Each Category of Percentage of Glycosylated Hemoglobin (HbA1c) According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist
≥8.5%
|
278 Participants
|
123 Participants
|
95 Participants
|
114 Participants
|
—
|
|
Clinical Parameter Relevant for Type 2 Diabetes (T2D): Number of Patients in Each Category of Percentage of Glycosylated Hemoglobin (HbA1c) According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist
Missing
|
153 Participants
|
48 Participants
|
14 Participants
|
36 Participants
|
—
|
PRIMARY outcome
Timeframe: At study index date 1 (i.e. between September 2018 and December 2018).Population: Patients of the prescribed patient set (PPS) who were initiated on type 2 diabetes (T2D) medication by cardiologist. PPS included all patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective T2D medication and whose documentation was electronically signed by the physician. Only patients with non-missing values are reported.
Clinical parameter relevant for type 2 diabetes (T2D): Percentage of glycosylated hemoglobin (HbA1c \[%\]) according to T2D medication for the patients who were initiated on T2D medication by cardiologist is reported.
Outcome measures
| Measure |
Patients Initiated on T2D Medication by Endocrinologist
n=50 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by endocrinologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Diabetologist
n=15 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by diabetologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Cardiologist
n=1 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by cardiologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on Other SGLT2i by Endocrinologist
n=5 Participants
Patients with type 2 diabetes from Central Eastern Europe (CEE) (i.e. Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who have been newly initiated (first ever use) on other sodium dependent glucose transporter inhibitor (SGLT2i) between September 2018 and December 2018 (study index date 1) by endocrinologist.
|
T2D Patients From Russian Federation
Patients with type 2 diabetes (T2D) from Russian Federation who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) between September 2018 and December 2018 (study index date 1) and have consented to documentation at study index date 2.
|
|---|---|---|---|---|---|
|
Clinical Parameter Relevant for Type 2 Diabetes (T2D): Percentage of Glycosylated Hemoglobin (HbA1c [%]) According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist
|
7.9 percentage of glycosylated hemoglobin
Standard Deviation 1.1
|
8.1 percentage of glycosylated hemoglobin
Standard Deviation 1.1
|
7.4 percentage of glycosylated hemoglobin
|
8.5 percentage of glycosylated hemoglobin
Standard Deviation 0.7
|
—
|
PRIMARY outcome
Timeframe: At study index date 1 (i.e. between September 2018 and December 2018).Population: Patients of the prescribed patient set (PPS) who were initiated on type 2 diabetes (T2D) medication by cardiologist. PPS included all patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective T2D medication and whose documentation was electronically signed by the physician.
Clinical parameter relevant for type 2 diabetes (T2D): Number of patients in each category of percentage of glycosylated hemoglobin (HbA1c) according to T2D medication for the patients who were initiated on T2D medication by cardiologist is reported. The reported categories of percentage of glycosylated hemoglobin are: * \<8.5% * ≥8.5% * Missing
Outcome measures
| Measure |
Patients Initiated on T2D Medication by Endocrinologist
n=78 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by endocrinologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Diabetologist
n=16 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by diabetologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Cardiologist
n=1 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by cardiologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on Other SGLT2i by Endocrinologist
n=7 Participants
Patients with type 2 diabetes from Central Eastern Europe (CEE) (i.e. Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who have been newly initiated (first ever use) on other sodium dependent glucose transporter inhibitor (SGLT2i) between September 2018 and December 2018 (study index date 1) by endocrinologist.
|
T2D Patients From Russian Federation
Patients with type 2 diabetes (T2D) from Russian Federation who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) between September 2018 and December 2018 (study index date 1) and have consented to documentation at study index date 2.
|
|---|---|---|---|---|---|
|
Clinical Parameter Relevant for Type 2 Diabetes (T2D): Number of Patients in Each Category of Percentage of Glycosylated Hemoglobin (HbA1c) According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist
<8.5%
|
36 Participants
|
11 Participants
|
1 Participants
|
3 Participants
|
—
|
|
Clinical Parameter Relevant for Type 2 Diabetes (T2D): Number of Patients in Each Category of Percentage of Glycosylated Hemoglobin (HbA1c) According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist
≥8.5%
|
14 Participants
|
4 Participants
|
0 Participants
|
2 Participants
|
—
|
|
Clinical Parameter Relevant for Type 2 Diabetes (T2D): Number of Patients in Each Category of Percentage of Glycosylated Hemoglobin (HbA1c) According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist
Missing
|
28 Participants
|
1 Participants
|
0 Participants
|
2 Participants
|
—
|
PRIMARY outcome
Timeframe: At study index date 1 (i.e. between September 2018 and December 2018).Population: Patients of the prescribed patient set (PPS) who were initiated on type 2 diabetes (T2D) medication by endocrinologist. PPS included all patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective T2D medication and whose documentation was electronically signed by the physician. Only patients with non-missing results are reported.
10-year risk for fatal cardiovascular disease (CVD) according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by endocrinologist is reported. 10-year risk for fatal CVD was calculated according to the applying Systematic COronary Risk Evaluation (SCORE) Risk Chart (European Society of Cardiology) which takes into account patient´s age, gender, systolic blood pressure, smoking status, and total cholesterol value at index date 1. SCORE Risk Chart takes values from from 0% to 100%. SCORE Risk Chart values from 5% and upwards indicate a high 10-year risk for a fatal cardiovascular event.
Outcome measures
| Measure |
Patients Initiated on T2D Medication by Endocrinologist
n=615 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by endocrinologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Diabetologist
n=403 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by diabetologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Cardiologist
n=62 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by cardiologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on Other SGLT2i by Endocrinologist
n=179 Participants
Patients with type 2 diabetes from Central Eastern Europe (CEE) (i.e. Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who have been newly initiated (first ever use) on other sodium dependent glucose transporter inhibitor (SGLT2i) between September 2018 and December 2018 (study index date 1) by endocrinologist.
|
T2D Patients From Russian Federation
Patients with type 2 diabetes (T2D) from Russian Federation who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) between September 2018 and December 2018 (study index date 1) and have consented to documentation at study index date 2.
|
|---|---|---|---|---|---|
|
10-year Risk for Fatal Cardiovascular Disease (CVD) According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist
|
6.4 Score on a scale
Standard Deviation 5.7
|
5.6 Score on a scale
Standard Deviation 4.7
|
4.3 Score on a scale
Standard Deviation 3.7
|
6.0 Score on a scale
Standard Deviation 5.7
|
—
|
PRIMARY outcome
Timeframe: At study index date 1 (i.e. between September 2018 and December 2018).Population: Patients of the prescribed patient set (PPS) who were initiated on type 2 diabetes (T2D) medication by diabetologist. PPS included all patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective T2D medication and whose documentation was electronically signed by the physician. Only patients with non-missing results are reported.
10-year risk for fatal cardiovascular disease (CVD) according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by diabetologist is reported. 10-year risk for fatal CVD was calculated according to the applying Systematic COronary Risk Evaluation (SCORE) Risk Chart (European Society of Cardiology) which takes into account patient´s age, gender, systolic blood pressure, smoking status, and total cholesterol value at index date 1. SCORE Risk Chart takes values from from 0% to 100%. SCORE Risk Chart values from 5% and upwards indicate a high 10-year risk for a fatal cardiovascular event.
Outcome measures
| Measure |
Patients Initiated on T2D Medication by Endocrinologist
n=609 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by endocrinologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Diabetologist
n=355 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by diabetologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Cardiologist
n=155 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by cardiologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on Other SGLT2i by Endocrinologist
n=164 Participants
Patients with type 2 diabetes from Central Eastern Europe (CEE) (i.e. Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who have been newly initiated (first ever use) on other sodium dependent glucose transporter inhibitor (SGLT2i) between September 2018 and December 2018 (study index date 1) by endocrinologist.
|
T2D Patients From Russian Federation
Patients with type 2 diabetes (T2D) from Russian Federation who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) between September 2018 and December 2018 (study index date 1) and have consented to documentation at study index date 2.
|
|---|---|---|---|---|---|
|
10-year Risk for Fatal Cardiovascular Disease (CVD) According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist
|
7.0 Score on a scale
Standard Deviation 5.5
|
7.0 Score on a scale
Standard Deviation 5.9
|
5.4 Score on a scale
Standard Deviation 4.7
|
6.5 Score on a scale
Standard Deviation 5.1
|
—
|
PRIMARY outcome
Timeframe: At study index date 1 (i.e. between September 2018 and December 2018).Population: Patients of the prescribed patient set (PPS) who were initiated on type 2 diabetes (T2D) medication by cardiologist. PPS included all patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective T2D medication and whose documentation was electronically signed by the physician. Only patients with non-missing results are reported.
10-year risk for fatal cardiovascular disease (CVD) according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by cardiologist is reported. 10-year risk for fatal CVD was calculated according to the applying Systematic COronary Risk Evaluation (SCORE) Risk Chart (European Society of Cardiology) which takes into account patient´s age, gender, systolic blood pressure, smoking status, and total cholesterol value at index date 1. SCORE Risk Chart takes values from from 0% to 100%. SCORE Risk Chart values from 5% and upwards indicate a high 10-year risk for a fatal cardiovascular event.
Outcome measures
| Measure |
Patients Initiated on T2D Medication by Endocrinologist
n=54 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by endocrinologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Diabetologist
n=11 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by diabetologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Cardiologist
n=1 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by cardiologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on Other SGLT2i by Endocrinologist
n=5 Participants
Patients with type 2 diabetes from Central Eastern Europe (CEE) (i.e. Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who have been newly initiated (first ever use) on other sodium dependent glucose transporter inhibitor (SGLT2i) between September 2018 and December 2018 (study index date 1) by endocrinologist.
|
T2D Patients From Russian Federation
Patients with type 2 diabetes (T2D) from Russian Federation who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) between September 2018 and December 2018 (study index date 1) and have consented to documentation at study index date 2.
|
|---|---|---|---|---|---|
|
10-year Risk for Fatal Cardiovascular Disease (CVD) According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist
|
8.9 Score on a scale
Standard Deviation 7.7
|
9.4 Score on a scale
Standard Deviation 7.8
|
5.0 Score on a scale
|
3.8 Score on a scale
Standard Deviation 2.3
|
—
|
PRIMARY outcome
Timeframe: At study index date 1 (i.e. between September 2018 and December 2018).Population: Patients of the prescribed patient set (PPS) who were initiated on type 2 diabetes (T2D) medication by endocrinologist. PPS included all patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective T2D medication and whose documentation was electronically signed by the physician.
Number of patients per type of medical specialty of other physicians involved in treatment decision according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by endocrinologist is reported.
Outcome measures
| Measure |
Patients Initiated on T2D Medication by Endocrinologist
n=815 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by endocrinologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Diabetologist
n=504 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by diabetologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Cardiologist
n=89 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by cardiologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on Other SGLT2i by Endocrinologist
n=244 Participants
Patients with type 2 diabetes from Central Eastern Europe (CEE) (i.e. Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who have been newly initiated (first ever use) on other sodium dependent glucose transporter inhibitor (SGLT2i) between September 2018 and December 2018 (study index date 1) by endocrinologist.
|
T2D Patients From Russian Federation
Patients with type 2 diabetes (T2D) from Russian Federation who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) between September 2018 and December 2018 (study index date 1) and have consented to documentation at study index date 2.
|
|---|---|---|---|---|---|
|
Number of Patients Per Type of Medical Specialty of Other Physicians Involved in Treatment Decision According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist
Other endocrinologist
|
56 Participants
|
36 Participants
|
1 Participants
|
11 Participants
|
—
|
|
Number of Patients Per Type of Medical Specialty of Other Physicians Involved in Treatment Decision According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist
Diabetologist
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
—
|
|
Number of Patients Per Type of Medical Specialty of Other Physicians Involved in Treatment Decision According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist
Cardiologist
|
81 Participants
|
25 Participants
|
7 Participants
|
19 Participants
|
—
|
|
Number of Patients Per Type of Medical Specialty of Other Physicians Involved in Treatment Decision According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist
Nephrologist
|
8 Participants
|
8 Participants
|
2 Participants
|
0 Participants
|
—
|
|
Number of Patients Per Type of Medical Specialty of Other Physicians Involved in Treatment Decision According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist
General practitioner
|
46 Participants
|
33 Participants
|
7 Participants
|
12 Participants
|
—
|
|
Number of Patients Per Type of Medical Specialty of Other Physicians Involved in Treatment Decision According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist
Others
|
3 Participants
|
5 Participants
|
3 Participants
|
1 Participants
|
—
|
|
Number of Patients Per Type of Medical Specialty of Other Physicians Involved in Treatment Decision According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist
None
|
697 Participants
|
439 Participants
|
76 Participants
|
209 Participants
|
—
|
PRIMARY outcome
Timeframe: At study index date 1 (i.e. between September 2018 and December 2018).Population: Patients of the prescribed patient set (PPS) who were initiated on type 2 diabetes (T2D) medication by diabetologist. PPS included all patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective T2D medication and whose documentation was electronically signed by the physician.
Number of patients per type of medical specialty of other physicians involved in treatment decision according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by diabetologist is reported.
Outcome measures
| Measure |
Patients Initiated on T2D Medication by Endocrinologist
n=1073 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by endocrinologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Diabetologist
n=624 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by diabetologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Cardiologist
n=271 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by cardiologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on Other SGLT2i by Endocrinologist
n=333 Participants
Patients with type 2 diabetes from Central Eastern Europe (CEE) (i.e. Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who have been newly initiated (first ever use) on other sodium dependent glucose transporter inhibitor (SGLT2i) between September 2018 and December 2018 (study index date 1) by endocrinologist.
|
T2D Patients From Russian Federation
Patients with type 2 diabetes (T2D) from Russian Federation who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) between September 2018 and December 2018 (study index date 1) and have consented to documentation at study index date 2.
|
|---|---|---|---|---|---|
|
Number of Patients Per Type of Medical Specialty of Other Physicians Involved in Treatment Decision According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist
Endocrinologist
|
3 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
—
|
|
Number of Patients Per Type of Medical Specialty of Other Physicians Involved in Treatment Decision According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist
Other diabetologist
|
74 Participants
|
35 Participants
|
11 Participants
|
24 Participants
|
—
|
|
Number of Patients Per Type of Medical Specialty of Other Physicians Involved in Treatment Decision According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist
Cardiologist
|
35 Participants
|
2 Participants
|
2 Participants
|
3 Participants
|
—
|
|
Number of Patients Per Type of Medical Specialty of Other Physicians Involved in Treatment Decision According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist
Nephrologist
|
1 Participants
|
5 Participants
|
0 Participants
|
0 Participants
|
—
|
|
Number of Patients Per Type of Medical Specialty of Other Physicians Involved in Treatment Decision According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist
General practitioner
|
25 Participants
|
6 Participants
|
1 Participants
|
7 Participants
|
—
|
|
Number of Patients Per Type of Medical Specialty of Other Physicians Involved in Treatment Decision According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist
Others
|
0 Participants
|
1 Participants
|
0 Participants
|
1 Participants
|
—
|
|
Number of Patients Per Type of Medical Specialty of Other Physicians Involved in Treatment Decision According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist
None
|
953 Participants
|
577 Participants
|
257 Participants
|
300 Participants
|
—
|
PRIMARY outcome
Timeframe: At study index date 1 (i.e. between September 2018 and December 2018).Population: Patients of the prescribed patient set (PPS) who were initiated on type 2 diabetes (T2D) medication by cardiologist. PPS included all patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective T2D medication and whose documentation was electronically signed by the physician.
Number of patients per type of medical specialty of other physicians involved in treatment decision according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by cardiologist is reported.
Outcome measures
| Measure |
Patients Initiated on T2D Medication by Endocrinologist
n=78 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by endocrinologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Diabetologist
n=16 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by diabetologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Cardiologist
n=1 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by cardiologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on Other SGLT2i by Endocrinologist
n=7 Participants
Patients with type 2 diabetes from Central Eastern Europe (CEE) (i.e. Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who have been newly initiated (first ever use) on other sodium dependent glucose transporter inhibitor (SGLT2i) between September 2018 and December 2018 (study index date 1) by endocrinologist.
|
T2D Patients From Russian Federation
Patients with type 2 diabetes (T2D) from Russian Federation who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) between September 2018 and December 2018 (study index date 1) and have consented to documentation at study index date 2.
|
|---|---|---|---|---|---|
|
Number of Patients Per Type of Medical Specialty of Other Physicians Involved in Treatment Decision According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist
Diabetologist
|
10 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
—
|
|
Number of Patients Per Type of Medical Specialty of Other Physicians Involved in Treatment Decision According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist
None
|
45 Participants
|
12 Participants
|
1 Participants
|
7 Participants
|
—
|
|
Number of Patients Per Type of Medical Specialty of Other Physicians Involved in Treatment Decision According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist
Endocrinologist
|
19 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
—
|
|
Number of Patients Per Type of Medical Specialty of Other Physicians Involved in Treatment Decision According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist
Other cardiologist
|
4 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
—
|
|
Number of Patients Per Type of Medical Specialty of Other Physicians Involved in Treatment Decision According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist
Nephrologist
|
1 Participants
|
3 Participants
|
0 Participants
|
0 Participants
|
—
|
|
Number of Patients Per Type of Medical Specialty of Other Physicians Involved in Treatment Decision According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist
General practitioner
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
—
|
|
Number of Patients Per Type of Medical Specialty of Other Physicians Involved in Treatment Decision According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist
Others
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
—
|
SECONDARY outcome
Timeframe: At study index date 1 (i.e. between September 2018 and December 2018).Population: Prescribed patient set (PPS): All patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective type 2 diabetes (T2D) medication and whose documentation was electronically signed by the physician.
Number of patients with cardiovascular disease (CVD) is reported. Patients with cardiovascular disease were considered patients for whom 'History of acute myocardial infarction', 'History of cardiology intervention', 'Ischemic heart disease', 'Congestive heart failure', 'History of stroke' or 'Peripheral arterial disease', were documented as comorbidities.
Outcome measures
| Measure |
Patients Initiated on T2D Medication by Endocrinologist
n=4055 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by endocrinologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Diabetologist
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by diabetologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Cardiologist
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by cardiologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on Other SGLT2i by Endocrinologist
Patients with type 2 diabetes from Central Eastern Europe (CEE) (i.e. Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who have been newly initiated (first ever use) on other sodium dependent glucose transporter inhibitor (SGLT2i) between September 2018 and December 2018 (study index date 1) by endocrinologist.
|
T2D Patients From Russian Federation
Patients with type 2 diabetes (T2D) from Russian Federation who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) between September 2018 and December 2018 (study index date 1) and have consented to documentation at study index date 2.
|
|---|---|---|---|---|---|
|
Number of Patients With Any Type of Cardiovascular Disease (CVD)
|
1485 Participants
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: At study index date 1 (i.e. between September 2018 and December 2018).Population: Prescribed patient set (PPS): All patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective type 2 diabetes (T2D) medication and whose documentation was electronically signed by the physician.
Number of patients with chronic kidney disease (CKD) by physician's assessment (patients for whom CKD was reported as a comorbidity) is reported.
Outcome measures
| Measure |
Patients Initiated on T2D Medication by Endocrinologist
n=4055 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by endocrinologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Diabetologist
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by diabetologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Cardiologist
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by cardiologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on Other SGLT2i by Endocrinologist
Patients with type 2 diabetes from Central Eastern Europe (CEE) (i.e. Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who have been newly initiated (first ever use) on other sodium dependent glucose transporter inhibitor (SGLT2i) between September 2018 and December 2018 (study index date 1) by endocrinologist.
|
T2D Patients From Russian Federation
Patients with type 2 diabetes (T2D) from Russian Federation who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) between September 2018 and December 2018 (study index date 1) and have consented to documentation at study index date 2.
|
|---|---|---|---|---|---|
|
Number of Patients With Chronic Kidney Disease (CKD) by Physician's Assessment
|
586 Participants
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: At study index date 1 (i.e. between September 2018 and December 2018).Population: Prescribed patient set (PPS): All patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective type 2 diabetes (T2D) medication and whose documentation was electronically signed by the physician.
Number of patients with documentation of estimated Glomerular Filtration Rate (eGFR) / Urine Albumin Creatinine Ratio (UACR) status is reported.
Outcome measures
| Measure |
Patients Initiated on T2D Medication by Endocrinologist
n=4055 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by endocrinologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Diabetologist
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by diabetologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Cardiologist
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by cardiologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on Other SGLT2i by Endocrinologist
Patients with type 2 diabetes from Central Eastern Europe (CEE) (i.e. Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who have been newly initiated (first ever use) on other sodium dependent glucose transporter inhibitor (SGLT2i) between September 2018 and December 2018 (study index date 1) by endocrinologist.
|
T2D Patients From Russian Federation
Patients with type 2 diabetes (T2D) from Russian Federation who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) between September 2018 and December 2018 (study index date 1) and have consented to documentation at study index date 2.
|
|---|---|---|---|---|---|
|
Number of Patients With Documentation of Estimated Glomerular Filtration Rate (eGFR) / Urine Albumin Creatinine Ratio (UACR) Status
|
3175 Participants
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: At study index date 1 (i.e. between September 2018 and December 2018).Population: Patients in the Prescribed patient set (PPS) (all patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective type 2 diabetes (T2D) medication and whose documentation was electronically signed by the physician) with documentation of of eGFR / UACR status.
Number of patients with Chronic Kidney Disease (CKD) by estimated Glomerular Filtration Rate (eGFR) and Urine Albumin Creatinine Ratio (UACR) status is reported.
Outcome measures
| Measure |
Patients Initiated on T2D Medication by Endocrinologist
n=3175 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by endocrinologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Diabetologist
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by diabetologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Cardiologist
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by cardiologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on Other SGLT2i by Endocrinologist
Patients with type 2 diabetes from Central Eastern Europe (CEE) (i.e. Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who have been newly initiated (first ever use) on other sodium dependent glucose transporter inhibitor (SGLT2i) between September 2018 and December 2018 (study index date 1) by endocrinologist.
|
T2D Patients From Russian Federation
Patients with type 2 diabetes (T2D) from Russian Federation who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) between September 2018 and December 2018 (study index date 1) and have consented to documentation at study index date 2.
|
|---|---|---|---|---|---|
|
Number of Patients With Chronic Kidney Disease (CKD) by Estimated Glomerular Filtration Rate (eGFR) and Urine Albumin Creatinine Ratio (UACR) Status
|
886 Participants
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: At study index date 1 (i.e. between September 2018 and December 2018).Population: Prescribed patient set (PPS): All patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective type 2 diabetes (T2D) medication and whose documentation was electronically signed by the physician.
Number of patients in each category of the different types of cardiovascular disease is reported. The following types of cardiovascular diseases are reported: * Myocardial infarction * Cardiology intervention (Percutaneous Coronary Intervention (PCI) or Coronary Artery Bypass Grafting (CABG)) * Ischemic heart disease * Congestive heart failure * Stroke * Peripheral arterial disease The categories reported for each type of cardiovascular disease are: * Yes * No * Unknown
Outcome measures
| Measure |
Patients Initiated on T2D Medication by Endocrinologist
n=4055 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by endocrinologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Diabetologist
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by diabetologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Cardiologist
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by cardiologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on Other SGLT2i by Endocrinologist
Patients with type 2 diabetes from Central Eastern Europe (CEE) (i.e. Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who have been newly initiated (first ever use) on other sodium dependent glucose transporter inhibitor (SGLT2i) between September 2018 and December 2018 (study index date 1) by endocrinologist.
|
T2D Patients From Russian Federation
Patients with type 2 diabetes (T2D) from Russian Federation who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) between September 2018 and December 2018 (study index date 1) and have consented to documentation at study index date 2.
|
|---|---|---|---|---|---|
|
Number of Patients in Each Category of the Different Types of Cardiovascular Disease
Myocardial infarction · Yes
|
450 Participants
|
—
|
—
|
—
|
—
|
|
Number of Patients in Each Category of the Different Types of Cardiovascular Disease
Myocardial infarction · No
|
3558 Participants
|
—
|
—
|
—
|
—
|
|
Number of Patients in Each Category of the Different Types of Cardiovascular Disease
Myocardial infarction · Unknown
|
47 Participants
|
—
|
—
|
—
|
—
|
|
Number of Patients in Each Category of the Different Types of Cardiovascular Disease
Cardiology intervention (PCI or CABG) · Yes
|
525 Participants
|
—
|
—
|
—
|
—
|
|
Number of Patients in Each Category of the Different Types of Cardiovascular Disease
Cardiology intervention (PCI or CABG) · No
|
3471 Participants
|
—
|
—
|
—
|
—
|
|
Number of Patients in Each Category of the Different Types of Cardiovascular Disease
Cardiology intervention (PCI or CABG) · Unknown
|
59 Participants
|
—
|
—
|
—
|
—
|
|
Number of Patients in Each Category of the Different Types of Cardiovascular Disease
Ischemic heart disease · Yes
|
1087 Participants
|
—
|
—
|
—
|
—
|
|
Number of Patients in Each Category of the Different Types of Cardiovascular Disease
Ischemic heart disease · No
|
2910 Participants
|
—
|
—
|
—
|
—
|
|
Number of Patients in Each Category of the Different Types of Cardiovascular Disease
Ischemic heart disease · Unknown
|
58 Participants
|
—
|
—
|
—
|
—
|
|
Number of Patients in Each Category of the Different Types of Cardiovascular Disease
Congestive heart failure · Yes
|
421 Participants
|
—
|
—
|
—
|
—
|
|
Number of Patients in Each Category of the Different Types of Cardiovascular Disease
Congestive heart failure · No
|
3511 Participants
|
—
|
—
|
—
|
—
|
|
Number of Patients in Each Category of the Different Types of Cardiovascular Disease
Congestive heart failure · Unknown
|
123 Participants
|
—
|
—
|
—
|
—
|
|
Number of Patients in Each Category of the Different Types of Cardiovascular Disease
Stroke · Yes
|
248 Participants
|
—
|
—
|
—
|
—
|
|
Number of Patients in Each Category of the Different Types of Cardiovascular Disease
Stroke · No
|
3764 Participants
|
—
|
—
|
—
|
—
|
|
Number of Patients in Each Category of the Different Types of Cardiovascular Disease
Stroke · Unknown
|
43 Participants
|
—
|
—
|
—
|
—
|
|
Number of Patients in Each Category of the Different Types of Cardiovascular Disease
Peripheral arterial disease · Yes
|
350 Participants
|
—
|
—
|
—
|
—
|
|
Number of Patients in Each Category of the Different Types of Cardiovascular Disease
Peripheral arterial disease · No
|
3643 Participants
|
—
|
—
|
—
|
—
|
|
Number of Patients in Each Category of the Different Types of Cardiovascular Disease
Peripheral arterial disease · Unknown
|
62 Participants
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: At study index date 1 (i.e. between September 2018 and December 2018).Population: Patients in the Prescribed patient set (PPS) (all patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective type 2 diabetes (T2D) medication and whose documentation was electronically signed by the physician) with congestive heart failure.
Number of patients in each category of the different types of congestive heart failure (CHF) which was confirmed by echocardiography is reported. The reported categories of congestive heart failure confirmed by echocardiography are: * Yes * No * Unknown
Outcome measures
| Measure |
Patients Initiated on T2D Medication by Endocrinologist
n=421 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by endocrinologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Diabetologist
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by diabetologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Cardiologist
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by cardiologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on Other SGLT2i by Endocrinologist
Patients with type 2 diabetes from Central Eastern Europe (CEE) (i.e. Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who have been newly initiated (first ever use) on other sodium dependent glucose transporter inhibitor (SGLT2i) between September 2018 and December 2018 (study index date 1) by endocrinologist.
|
T2D Patients From Russian Federation
Patients with type 2 diabetes (T2D) from Russian Federation who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) between September 2018 and December 2018 (study index date 1) and have consented to documentation at study index date 2.
|
|---|---|---|---|---|---|
|
Number of Patients in Each Category of the Different Types of Congestive Heart Failure (CHF) - Confirmed by Echocardiography
Yes
|
245 Participants
|
—
|
—
|
—
|
—
|
|
Number of Patients in Each Category of the Different Types of Congestive Heart Failure (CHF) - Confirmed by Echocardiography
No
|
86 Participants
|
—
|
—
|
—
|
—
|
|
Number of Patients in Each Category of the Different Types of Congestive Heart Failure (CHF) - Confirmed by Echocardiography
Unknown
|
90 Participants
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: At study index date 1 (i.e. between September 2018 and December 2018).Population: Prescribed patient set (PPS): All patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective type 2 diabetes (T2D) medication and whose documentation was electronically signed by the physician.
Number of patients with any type of cardiovascular disease (CVD) or without CVD according to prescribing specialist is reported. Patients with cardiovascular disease were considered patients for whom 'History of acute myocardial infarction', 'History of cardiology intervention', 'Ischemic heart disease', 'Congestive heart failure', 'History of stroke' or 'Peripheral arterial disease', were documented as comorbidities.
Outcome measures
| Measure |
Patients Initiated on T2D Medication by Endocrinologist
n=1652 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by endocrinologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Diabetologist
n=2301 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by diabetologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Cardiologist
n=102 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by cardiologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on Other SGLT2i by Endocrinologist
Patients with type 2 diabetes from Central Eastern Europe (CEE) (i.e. Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who have been newly initiated (first ever use) on other sodium dependent glucose transporter inhibitor (SGLT2i) between September 2018 and December 2018 (study index date 1) by endocrinologist.
|
T2D Patients From Russian Federation
Patients with type 2 diabetes (T2D) from Russian Federation who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) between September 2018 and December 2018 (study index date 1) and have consented to documentation at study index date 2.
|
|---|---|---|---|---|---|
|
Number of Patients With Any Type of Cardiovascular Disease (CVD) and Without CVD According to Prescribing Specialist
Patients with any type of CVD
|
736 Participants
|
656 Participants
|
93 Participants
|
—
|
—
|
|
Number of Patients With Any Type of Cardiovascular Disease (CVD) and Without CVD According to Prescribing Specialist
Patients without CVD
|
916 Participants
|
1645 Participants
|
9 Participants
|
—
|
—
|
SECONDARY outcome
Timeframe: At study index date 1 (i.e. between September 2018 and December 2018).Population: Prescribed patient set (PPS): All patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective type 2 diabetes (T2D) medication and whose documentation was electronically signed by the physician.
Number of patients with chronic kidney (CKD) and without CKD by physician's assessment according to prescribing specialist is reported.
Outcome measures
| Measure |
Patients Initiated on T2D Medication by Endocrinologist
n=1652 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by endocrinologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Diabetologist
n=2301 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by diabetologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Cardiologist
n=102 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by cardiologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on Other SGLT2i by Endocrinologist
Patients with type 2 diabetes from Central Eastern Europe (CEE) (i.e. Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who have been newly initiated (first ever use) on other sodium dependent glucose transporter inhibitor (SGLT2i) between September 2018 and December 2018 (study index date 1) by endocrinologist.
|
T2D Patients From Russian Federation
Patients with type 2 diabetes (T2D) from Russian Federation who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) between September 2018 and December 2018 (study index date 1) and have consented to documentation at study index date 2.
|
|---|---|---|---|---|---|
|
Number of Patients With Chronic Kidney (CKD) (Patients for Whom CKD Was Reported as a Comorbidity) or Without CKD by Physician's Assessment According to Prescribing Specialist
Patients with CKD by physician's assessment
|
327 Participants
|
244 Participants
|
15 Participants
|
—
|
—
|
|
Number of Patients With Chronic Kidney (CKD) (Patients for Whom CKD Was Reported as a Comorbidity) or Without CKD by Physician's Assessment According to Prescribing Specialist
Patients without CKD by physician's assessment
|
1325 Participants
|
2057 Participants
|
87 Participants
|
—
|
—
|
SECONDARY outcome
Timeframe: At study index date 1 (i.e. between September 2018 and December 2018).Population: Patients in the Prescribed patient set (PPS) (all patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective type 2 diabetes (T2D) medication and whose documentation was electronically signed by the physician) with documentation of eGFR and/or UACR status are reported.
Number of patients with chronic kidney disease (CKD) by estimated Glomerular Filtration Rate (eGFR) and Urine Albumin Creatinine Ratio (UACR) status - according to prescribing specialist is reported.
Outcome measures
| Measure |
Patients Initiated on T2D Medication by Endocrinologist
n=1493 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by endocrinologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Diabetologist
n=1604 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by diabetologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Cardiologist
n=78 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by cardiologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on Other SGLT2i by Endocrinologist
Patients with type 2 diabetes from Central Eastern Europe (CEE) (i.e. Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who have been newly initiated (first ever use) on other sodium dependent glucose transporter inhibitor (SGLT2i) between September 2018 and December 2018 (study index date 1) by endocrinologist.
|
T2D Patients From Russian Federation
Patients with type 2 diabetes (T2D) from Russian Federation who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) between September 2018 and December 2018 (study index date 1) and have consented to documentation at study index date 2.
|
|---|---|---|---|---|---|
|
Number of Patients With Chronic Kidney Disease (CKD) by eGFR and UACR Status According to Prescribing Specialist
|
508 Participants
|
358 Participants
|
20 Participants
|
—
|
—
|
SECONDARY outcome
Timeframe: At study index date 1 (i.e. between September 2018 and December 2018).Population: Prescribed patient set (PPS): All patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective type 2 diabetes (T2D) medication and whose documentation was electronically signed by the physician.
Number of patients with or without at least one cardiovascular disease (CVD) type according to type 2 diabetes (T2D) medication initiated at study index date 1 is reported. Patients with cardiovascular disease were considered patients for whom 'History of acute myocardial infarction', 'History of cardiology intervention', 'Ischemic heart disease', 'Congestive heart failure', 'History of stroke' or 'Peripheral arterial disease', were documented as comorbidities.
Outcome measures
| Measure |
Patients Initiated on T2D Medication by Endocrinologist
n=1966 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by endocrinologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Diabetologist
n=1144 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by diabetologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Cardiologist
n=361 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by cardiologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on Other SGLT2i by Endocrinologist
n=584 Participants
Patients with type 2 diabetes from Central Eastern Europe (CEE) (i.e. Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who have been newly initiated (first ever use) on other sodium dependent glucose transporter inhibitor (SGLT2i) between September 2018 and December 2018 (study index date 1) by endocrinologist.
|
T2D Patients From Russian Federation
Patients with type 2 diabetes (T2D) from Russian Federation who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) between September 2018 and December 2018 (study index date 1) and have consented to documentation at study index date 2.
|
|---|---|---|---|---|---|
|
Number of Patients With or Without at Least One Cardiovascular Disease (CVD) Type According to Type 2 Diabetes (T2D) Medication Initiated at Study Index Date 1
Yes
|
812 Participants
|
398 Participants
|
75 Participants
|
200 Participants
|
—
|
|
Number of Patients With or Without at Least One Cardiovascular Disease (CVD) Type According to Type 2 Diabetes (T2D) Medication Initiated at Study Index Date 1
No
|
1154 Participants
|
746 Participants
|
286 Participants
|
384 Participants
|
—
|
SECONDARY outcome
Timeframe: At study index date 1 (i.e. between September 2018 and December 2018).Population: Prescribed patient set (PPS): All patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective type 2 diabetes (T2D) medication and whose documentation was electronically signed by the physician.
Number of patients in each category of different types of cardiovascular disease (CVD) according to type 2 diabetes (T2D) medication initiated at study index date 1 is reported. The following types of cardiovascular diseases are reported: * Myocardial infarction * Cardiology intervention (Percutaneous Coronary Intervention (PCI) or Coronary Artery Bypass Grafting (CABG)) * Ischemic heart disease * Congestive heart failure * Stroke * Peripheral arterial disease The categories reported for each type of cardiovascular disease are: * Yes * No * Unknown
Outcome measures
| Measure |
Patients Initiated on T2D Medication by Endocrinologist
n=1966 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by endocrinologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Diabetologist
n=1144 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by diabetologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Cardiologist
n=361 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by cardiologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on Other SGLT2i by Endocrinologist
n=584 Participants
Patients with type 2 diabetes from Central Eastern Europe (CEE) (i.e. Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who have been newly initiated (first ever use) on other sodium dependent glucose transporter inhibitor (SGLT2i) between September 2018 and December 2018 (study index date 1) by endocrinologist.
|
T2D Patients From Russian Federation
Patients with type 2 diabetes (T2D) from Russian Federation who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) between September 2018 and December 2018 (study index date 1) and have consented to documentation at study index date 2.
|
|---|---|---|---|---|---|
|
Number of Patients in Each Category of Different Types of Cardiovascular Disease (CVD) According to Type 2 Diabetes (T2D) Medication Initiated at Study Index Date 1
Peripheral arterial disease · Yes
|
171 Participants
|
118 Participants
|
15 Participants
|
46 Participants
|
—
|
|
Number of Patients in Each Category of Different Types of Cardiovascular Disease (CVD) According to Type 2 Diabetes (T2D) Medication Initiated at Study Index Date 1
Myocardial infarction · Yes
|
276 Participants
|
91 Participants
|
22 Participants
|
61 Participants
|
—
|
|
Number of Patients in Each Category of Different Types of Cardiovascular Disease (CVD) According to Type 2 Diabetes (T2D) Medication Initiated at Study Index Date 1
Myocardial infarction · No
|
1667 Participants
|
1039 Participants
|
334 Participants
|
518 Participants
|
—
|
|
Number of Patients in Each Category of Different Types of Cardiovascular Disease (CVD) According to Type 2 Diabetes (T2D) Medication Initiated at Study Index Date 1
Myocardial infarction · Unknown
|
23 Participants
|
14 Participants
|
5 Participants
|
5 Participants
|
—
|
|
Number of Patients in Each Category of Different Types of Cardiovascular Disease (CVD) According to Type 2 Diabetes (T2D) Medication Initiated at Study Index Date 1
Cardiology intervention (PCI or CABG) · Yes
|
328 Participants
|
98 Participants
|
30 Participants
|
69 Participants
|
—
|
|
Number of Patients in Each Category of Different Types of Cardiovascular Disease (CVD) According to Type 2 Diabetes (T2D) Medication Initiated at Study Index Date 1
Cardiology intervention (PCI or CABG) · No
|
1614 Participants
|
1024 Participants
|
324 Participants
|
509 Participants
|
—
|
|
Number of Patients in Each Category of Different Types of Cardiovascular Disease (CVD) According to Type 2 Diabetes (T2D) Medication Initiated at Study Index Date 1
Cardiology intervention (PCI or CABG) · Unknown
|
24 Participants
|
22 Participants
|
7 Participants
|
6 Participants
|
—
|
|
Number of Patients in Each Category of Different Types of Cardiovascular Disease (CVD) According to Type 2 Diabetes (T2D) Medication Initiated at Study Index Date 1
Ischemic heart disease · Yes
|
631 Participants
|
265 Participants
|
50 Participants
|
141 Participants
|
—
|
|
Number of Patients in Each Category of Different Types of Cardiovascular Disease (CVD) According to Type 2 Diabetes (T2D) Medication Initiated at Study Index Date 1
Ischemic heart disease · No
|
1312 Participants
|
860 Participants
|
305 Participants
|
433 Participants
|
—
|
|
Number of Patients in Each Category of Different Types of Cardiovascular Disease (CVD) According to Type 2 Diabetes (T2D) Medication Initiated at Study Index Date 1
Ischemic heart disease · Unknown
|
23 Participants
|
19 Participants
|
6 Participants
|
10 Participants
|
—
|
|
Number of Patients in Each Category of Different Types of Cardiovascular Disease (CVD) According to Type 2 Diabetes (T2D) Medication Initiated at Study Index Date 1
Congestive heart failure · Yes
|
252 Participants
|
104 Participants
|
14 Participants
|
51 Participants
|
—
|
|
Number of Patients in Each Category of Different Types of Cardiovascular Disease (CVD) According to Type 2 Diabetes (T2D) Medication Initiated at Study Index Date 1
Congestive heart failure · No
|
1664 Participants
|
997 Participants
|
337 Participants
|
513 Participants
|
—
|
|
Number of Patients in Each Category of Different Types of Cardiovascular Disease (CVD) According to Type 2 Diabetes (T2D) Medication Initiated at Study Index Date 1
Congestive heart failure · Unknown
|
50 Participants
|
43 Participants
|
10 Participants
|
20 Participants
|
—
|
|
Number of Patients in Each Category of Different Types of Cardiovascular Disease (CVD) According to Type 2 Diabetes (T2D) Medication Initiated at Study Index Date 1
Stroke · Yes
|
128 Participants
|
76 Participants
|
12 Participants
|
32 Participants
|
—
|
|
Number of Patients in Each Category of Different Types of Cardiovascular Disease (CVD) According to Type 2 Diabetes (T2D) Medication Initiated at Study Index Date 1
Stroke · No
|
1819 Participants
|
1056 Participants
|
342 Participants
|
547 Participants
|
—
|
|
Number of Patients in Each Category of Different Types of Cardiovascular Disease (CVD) According to Type 2 Diabetes (T2D) Medication Initiated at Study Index Date 1
Stroke · Unknown
|
19 Participants
|
12 Participants
|
7 Participants
|
5 Participants
|
—
|
|
Number of Patients in Each Category of Different Types of Cardiovascular Disease (CVD) According to Type 2 Diabetes (T2D) Medication Initiated at Study Index Date 1
Peripheral arterial disease · No
|
1767 Participants
|
1008 Participants
|
339 Participants
|
529 Participants
|
—
|
|
Number of Patients in Each Category of Different Types of Cardiovascular Disease (CVD) According to Type 2 Diabetes (T2D) Medication Initiated at Study Index Date 1
Peripheral arterial disease · Unknown
|
28 Participants
|
18 Participants
|
7 Participants
|
9 Participants
|
—
|
SECONDARY outcome
Timeframe: At study index date 1 (i.e. between September 2018 and December 2018).Population: Patients in the Prescribed patient set (PPS) (all patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective type 2 diabetes (T2D) medication and whose documentation was electronically signed by the physician) with congestive heart failure.
Number of patients in each category of congestive heart failure (CHF) confirmed by echocardiography according to type 2 diabetes (T2D) medication initiated at study index date 1 is reported.
Outcome measures
| Measure |
Patients Initiated on T2D Medication by Endocrinologist
n=252 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by endocrinologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Diabetologist
n=104 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by diabetologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Cardiologist
n=14 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by cardiologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on Other SGLT2i by Endocrinologist
n=51 Participants
Patients with type 2 diabetes from Central Eastern Europe (CEE) (i.e. Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who have been newly initiated (first ever use) on other sodium dependent glucose transporter inhibitor (SGLT2i) between September 2018 and December 2018 (study index date 1) by endocrinologist.
|
T2D Patients From Russian Federation
Patients with type 2 diabetes (T2D) from Russian Federation who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) between September 2018 and December 2018 (study index date 1) and have consented to documentation at study index date 2.
|
|---|---|---|---|---|---|
|
Number of Patients in Each Category of Congestive Heart Failure (CHF) Confirmed by Echocardiography According to Type 2 Diabetes (T2D) Medication Initiated at Study Index Date 1
No
|
36 Participants
|
39 Participants
|
4 Participants
|
7 Participants
|
—
|
|
Number of Patients in Each Category of Congestive Heart Failure (CHF) Confirmed by Echocardiography According to Type 2 Diabetes (T2D) Medication Initiated at Study Index Date 1
Yes
|
164 Participants
|
42 Participants
|
9 Participants
|
30 Participants
|
—
|
|
Number of Patients in Each Category of Congestive Heart Failure (CHF) Confirmed by Echocardiography According to Type 2 Diabetes (T2D) Medication Initiated at Study Index Date 1
Unknown
|
52 Participants
|
23 Participants
|
1 Participants
|
14 Participants
|
—
|
SECONDARY outcome
Timeframe: At study index date 1 (i.e. between September 2018 and December 2018).Population: Patients of the prescribed patient set (PPS) who were initiated on type 2 diabetes (T2D) medication by endocrinologist. PPS included all patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective T2D medication and whose documentation was electronically signed by the physician.
Number of patients with or without at least one cardiovascular disease (CVD) type according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by endocrinologist is reported. Patients with cardiovascular disease were considered patients for whom 'History of acute myocardial infarction', 'History of cardiology intervention', 'Ischemic heart disease', 'Congestive heart failure', 'History of stroke' or 'Peripheral arterial disease', were documented as comorbidities.
Outcome measures
| Measure |
Patients Initiated on T2D Medication by Endocrinologist
n=815 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by endocrinologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Diabetologist
n=504 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by diabetologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Cardiologist
n=89 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by cardiologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on Other SGLT2i by Endocrinologist
n=244 Participants
Patients with type 2 diabetes from Central Eastern Europe (CEE) (i.e. Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who have been newly initiated (first ever use) on other sodium dependent glucose transporter inhibitor (SGLT2i) between September 2018 and December 2018 (study index date 1) by endocrinologist.
|
T2D Patients From Russian Federation
Patients with type 2 diabetes (T2D) from Russian Federation who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) between September 2018 and December 2018 (study index date 1) and have consented to documentation at study index date 2.
|
|---|---|---|---|---|---|
|
Number of Patients With or Without at Least One Cardiovascular Disease (CVD) Type According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication From by Endocrinologist
Yes
|
380 Participants
|
229 Participants
|
28 Participants
|
99 Participants
|
—
|
|
Number of Patients With or Without at Least One Cardiovascular Disease (CVD) Type According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication From by Endocrinologist
No
|
435 Participants
|
275 Participants
|
61 Participants
|
145 Participants
|
—
|
SECONDARY outcome
Timeframe: At study index date 1 (i.e. between September 2018 and December 2018).Population: Patients of the prescribed patient set (PPS) who were initiated on type 2 diabetes (T2D) medication by diabetologist. PPS included all patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective T2D medication and whose documentation was electronically signed by the physician.
Number of patients with or without at least one cardiovascular disease (CVD) type according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by diabetologist is reported. Patients with cardiovascular disease were considered patients for whom 'History of acute myocardial infarction', 'History of cardiology intervention', 'Ischemic heart disease', 'Congestive heart failure', 'History of stroke' or 'Peripheral arterial disease', were documented as comorbidities.
Outcome measures
| Measure |
Patients Initiated on T2D Medication by Endocrinologist
n=1073 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by endocrinologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Diabetologist
n=624 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by diabetologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Cardiologist
n=271 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by cardiologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on Other SGLT2i by Endocrinologist
n=333 Participants
Patients with type 2 diabetes from Central Eastern Europe (CEE) (i.e. Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who have been newly initiated (first ever use) on other sodium dependent glucose transporter inhibitor (SGLT2i) between September 2018 and December 2018 (study index date 1) by endocrinologist.
|
T2D Patients From Russian Federation
Patients with type 2 diabetes (T2D) from Russian Federation who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) between September 2018 and December 2018 (study index date 1) and have consented to documentation at study index date 2.
|
|---|---|---|---|---|---|
|
Number of Patients With or Without at Least One Cardiovascular Disease (CVD) Type According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist
Yes
|
362 Participants
|
154 Participants
|
46 Participants
|
94 Participants
|
—
|
|
Number of Patients With or Without at Least One Cardiovascular Disease (CVD) Type According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist
No
|
711 Participants
|
470 Participants
|
225 Participants
|
239 Participants
|
—
|
SECONDARY outcome
Timeframe: At study index date 1 (i.e. between September 2018 and December 2018).Population: Patients of the prescribed patient set (PPS) who were initiated on type 2 diabetes (T2D) medication by cardiologist. PPS included all patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective T2D medication and whose documentation was electronically signed by the physician.
Number of patients with or without at least one cardiovascular disease (CVD) type according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by cardiologist is reported. Patients with cardiovascular disease were considered patients for whom 'History of acute myocardial infarction', 'History of cardiology intervention', 'Ischemic heart disease', 'Congestive heart failure', 'History of stroke' or 'Peripheral arterial disease', were documented as comorbidities.
Outcome measures
| Measure |
Patients Initiated on T2D Medication by Endocrinologist
n=78 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by endocrinologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Diabetologist
n=16 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by diabetologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Cardiologist
n=1 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by cardiologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on Other SGLT2i by Endocrinologist
n=7 Participants
Patients with type 2 diabetes from Central Eastern Europe (CEE) (i.e. Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who have been newly initiated (first ever use) on other sodium dependent glucose transporter inhibitor (SGLT2i) between September 2018 and December 2018 (study index date 1) by endocrinologist.
|
T2D Patients From Russian Federation
Patients with type 2 diabetes (T2D) from Russian Federation who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) between September 2018 and December 2018 (study index date 1) and have consented to documentation at study index date 2.
|
|---|---|---|---|---|---|
|
Number of Patients With or Without at Least One Cardiovascular Disease (CVD) Type According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist
Yes
|
70 Participants
|
15 Participants
|
1 Participants
|
7 Participants
|
—
|
|
Number of Patients With or Without at Least One Cardiovascular Disease (CVD) Type According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist
No
|
8 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
—
|
SECONDARY outcome
Timeframe: At study index date 1 (i.e. between September 2018 and December 2018).Population: Prescribed patient set (PPS): All patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective type 2 diabetes (T2D) medication and whose documentation was electronically signed by the physician.
Number of patients with chronic kidney (CKD) (patients for whom CKD was reported as a comorbidity) or without CKD by physician's assessment according to type 2 diabetes (T2D) medication initiated at study index date 1 is reported.
Outcome measures
| Measure |
Patients Initiated on T2D Medication by Endocrinologist
n=1966 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by endocrinologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Diabetologist
n=1144 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by diabetologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Cardiologist
n=361 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by cardiologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on Other SGLT2i by Endocrinologist
n=584 Participants
Patients with type 2 diabetes from Central Eastern Europe (CEE) (i.e. Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who have been newly initiated (first ever use) on other sodium dependent glucose transporter inhibitor (SGLT2i) between September 2018 and December 2018 (study index date 1) by endocrinologist.
|
T2D Patients From Russian Federation
Patients with type 2 diabetes (T2D) from Russian Federation who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) between September 2018 and December 2018 (study index date 1) and have consented to documentation at study index date 2.
|
|---|---|---|---|---|---|
|
Number of Patients With Chronic Kidney (CKD) or Without CKD by Physician's Assessment According to Type 2 Diabetes (T2D) Medication Initiated at Study Index Date 1
Patients with CKD by physician's assessment
|
221 Participants
|
289 Participants
|
26 Participants
|
50 Participants
|
—
|
|
Number of Patients With Chronic Kidney (CKD) or Without CKD by Physician's Assessment According to Type 2 Diabetes (T2D) Medication Initiated at Study Index Date 1
Patients without CKD by physician's assessment
|
1745 Participants
|
855 Participants
|
335 Participants
|
534 Participants
|
—
|
SECONDARY outcome
Timeframe: At study index date 1 (i.e. between September 2018 and December 2018).Population: Patients in the prescribed patient set (PPS) with available eGFR and UACR status. PPS included all patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective type 2 diabetes (T2D) medication and whose documentation was electronically signed by the physician.
Number of patients with chronic kidney (CKD) (patients for whom CKD was reported as a comorbidity) and without CKD by estimated Glomerular Filtration Rate (eGFR) and Urine Albumin Creatinine Ratio (UACR) status according to type 2 diabetes (T2D) medication initiated at study index date 1 is reported.
Outcome measures
| Measure |
Patients Initiated on T2D Medication by Endocrinologist
n=1568 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by endocrinologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Diabetologist
n=907 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by diabetologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Cardiologist
n=265 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by cardiologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on Other SGLT2i by Endocrinologist
n=435 Participants
Patients with type 2 diabetes from Central Eastern Europe (CEE) (i.e. Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who have been newly initiated (first ever use) on other sodium dependent glucose transporter inhibitor (SGLT2i) between September 2018 and December 2018 (study index date 1) by endocrinologist.
|
T2D Patients From Russian Federation
Patients with type 2 diabetes (T2D) from Russian Federation who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) between September 2018 and December 2018 (study index date 1) and have consented to documentation at study index date 2.
|
|---|---|---|---|---|---|
|
Number of Patients With Chronic Kidney (CKD) and Without CKD by eGFR and UACR Status According to Type 2 Diabetes (T2D) Medication Initiated at Study Index Date 1
Patients with CKD by eGFR and UACR status
|
386 Participants
|
365 Participants
|
50 Participants
|
85 Participants
|
—
|
|
Number of Patients With Chronic Kidney (CKD) and Without CKD by eGFR and UACR Status According to Type 2 Diabetes (T2D) Medication Initiated at Study Index Date 1
Patients without CKD by eGFR and UACR status
|
1182 Participants
|
542 Participants
|
215 Participants
|
350 Participants
|
—
|
SECONDARY outcome
Timeframe: At study index date 1 (i.e. between September 2018 and December 2018).Population: Prescribed patient set (PPS): All patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective type 2 diabetes (T2D) medication and whose documentation was electronically signed by the physician.
Number of patients in each category of employment status according to type 2 diabetes (T2D) medication initiated at study index date 1 is reported. The categories of employment status are: * Employed * Not employed * Unknown
Outcome measures
| Measure |
Patients Initiated on T2D Medication by Endocrinologist
n=1966 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by endocrinologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Diabetologist
n=1144 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by diabetologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Cardiologist
n=361 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by cardiologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on Other SGLT2i by Endocrinologist
n=584 Participants
Patients with type 2 diabetes from Central Eastern Europe (CEE) (i.e. Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who have been newly initiated (first ever use) on other sodium dependent glucose transporter inhibitor (SGLT2i) between September 2018 and December 2018 (study index date 1) by endocrinologist.
|
T2D Patients From Russian Federation
Patients with type 2 diabetes (T2D) from Russian Federation who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) between September 2018 and December 2018 (study index date 1) and have consented to documentation at study index date 2.
|
|---|---|---|---|---|---|
|
Number of Patients in Each Category of Employment Status According to Type 2 Diabetes (T2D) Medication Initiated at Study Index Date 1
Employed
|
966 Participants
|
433 Participants
|
229 Participants
|
302 Participants
|
—
|
|
Number of Patients in Each Category of Employment Status According to Type 2 Diabetes (T2D) Medication Initiated at Study Index Date 1
Not employed
|
878 Participants
|
639 Participants
|
111 Participants
|
261 Participants
|
—
|
|
Number of Patients in Each Category of Employment Status According to Type 2 Diabetes (T2D) Medication Initiated at Study Index Date 1
Unknown
|
122 Participants
|
72 Participants
|
21 Participants
|
21 Participants
|
—
|
SECONDARY outcome
Timeframe: At study index date 1 (i.e. between September 2018 and December 2018).Population: Prescribed patient set (PPS): All patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective type 2 diabetes (T2D) medication and whose documentation was electronically signed by the physician.
Number of patients in each category of family status according to type 2 diabetes (T2D) medication initiated at study index date 1 is reported. The categories of family status are: * Single * Married * Divorced * Widowed * Unknown
Outcome measures
| Measure |
Patients Initiated on T2D Medication by Endocrinologist
n=1966 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by endocrinologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Diabetologist
n=1144 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by diabetologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Cardiologist
n=361 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by cardiologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on Other SGLT2i by Endocrinologist
n=584 Participants
Patients with type 2 diabetes from Central Eastern Europe (CEE) (i.e. Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who have been newly initiated (first ever use) on other sodium dependent glucose transporter inhibitor (SGLT2i) between September 2018 and December 2018 (study index date 1) by endocrinologist.
|
T2D Patients From Russian Federation
Patients with type 2 diabetes (T2D) from Russian Federation who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) between September 2018 and December 2018 (study index date 1) and have consented to documentation at study index date 2.
|
|---|---|---|---|---|---|
|
Number of Patients in Each Category of Family Status According to Type 2 Diabetes (T2D) Medication Initiated at Study Index Date 1
Single
|
124 Participants
|
86 Participants
|
26 Participants
|
42 Participants
|
—
|
|
Number of Patients in Each Category of Family Status According to Type 2 Diabetes (T2D) Medication Initiated at Study Index Date 1
Married
|
1339 Participants
|
668 Participants
|
252 Participants
|
411 Participants
|
—
|
|
Number of Patients in Each Category of Family Status According to Type 2 Diabetes (T2D) Medication Initiated at Study Index Date 1
Divorced
|
88 Participants
|
59 Participants
|
27 Participants
|
37 Participants
|
—
|
|
Number of Patients in Each Category of Family Status According to Type 2 Diabetes (T2D) Medication Initiated at Study Index Date 1
Widowed
|
143 Participants
|
147 Participants
|
19 Participants
|
31 Participants
|
—
|
|
Number of Patients in Each Category of Family Status According to Type 2 Diabetes (T2D) Medication Initiated at Study Index Date 1
Unknown
|
272 Participants
|
184 Participants
|
37 Participants
|
63 Participants
|
—
|
SECONDARY outcome
Timeframe: At study index date 1 (i.e. between September 2018 and December 2018).Population: Prescribed patient set (PPS): All patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective type 2 diabetes (T2D) medication and whose documentation was electronically signed by the physician.
Number of patients in each category of insurance status according to type 2 diabetes (T2D) medication initiated at study index date 1 is reported. The categories of insurance status are: * Not insured * Statutory insured * Privately insured * Unknown
Outcome measures
| Measure |
Patients Initiated on T2D Medication by Endocrinologist
n=1966 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by endocrinologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Diabetologist
n=1144 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by diabetologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Cardiologist
n=361 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by cardiologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on Other SGLT2i by Endocrinologist
n=584 Participants
Patients with type 2 diabetes from Central Eastern Europe (CEE) (i.e. Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who have been newly initiated (first ever use) on other sodium dependent glucose transporter inhibitor (SGLT2i) between September 2018 and December 2018 (study index date 1) by endocrinologist.
|
T2D Patients From Russian Federation
Patients with type 2 diabetes (T2D) from Russian Federation who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) between September 2018 and December 2018 (study index date 1) and have consented to documentation at study index date 2.
|
|---|---|---|---|---|---|
|
Number of Patients in Each Category of Insurance Status According to Type 2 Diabetes (T2D) Medication Initiated at Study Index Date 1
Not insured
|
50 Participants
|
13 Participants
|
3 Participants
|
11 Participants
|
—
|
|
Number of Patients in Each Category of Insurance Status According to Type 2 Diabetes (T2D) Medication Initiated at Study Index Date 1
Statutory insured
|
1725 Participants
|
1055 Participants
|
336 Participants
|
539 Participants
|
—
|
|
Number of Patients in Each Category of Insurance Status According to Type 2 Diabetes (T2D) Medication Initiated at Study Index Date 1
Privately insured
|
89 Participants
|
35 Participants
|
13 Participants
|
16 Participants
|
—
|
|
Number of Patients in Each Category of Insurance Status According to Type 2 Diabetes (T2D) Medication Initiated at Study Index Date 1
Unknown
|
102 Participants
|
41 Participants
|
9 Participants
|
18 Participants
|
—
|
SECONDARY outcome
Timeframe: At study index date 1 (i.e. between September 2018 and December 2018).Population: Patients of the prescribed patient set (PPS) who were initiated on type 2 diabetes (T2D) medication by endocrinologist. PPS included all patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective T2D medication and whose documentation was electronically signed by the physician.
Number of patients in each category of employment status according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by endocrinologist is reported. The categories of employment status are: * Employed * Not employed * Unknown
Outcome measures
| Measure |
Patients Initiated on T2D Medication by Endocrinologist
n=815 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by endocrinologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Diabetologist
n=504 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by diabetologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Cardiologist
n=89 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by cardiologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on Other SGLT2i by Endocrinologist
n=244 Participants
Patients with type 2 diabetes from Central Eastern Europe (CEE) (i.e. Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who have been newly initiated (first ever use) on other sodium dependent glucose transporter inhibitor (SGLT2i) between September 2018 and December 2018 (study index date 1) by endocrinologist.
|
T2D Patients From Russian Federation
Patients with type 2 diabetes (T2D) from Russian Federation who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) between September 2018 and December 2018 (study index date 1) and have consented to documentation at study index date 2.
|
|---|---|---|---|---|---|
|
Number of Patients in Each Category of Employment Status According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist
Employed
|
438 Participants
|
199 Participants
|
69 Participants
|
128 Participants
|
—
|
|
Number of Patients in Each Category of Employment Status According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist
Not employed
|
345 Participants
|
286 Participants
|
17 Participants
|
109 Participants
|
—
|
|
Number of Patients in Each Category of Employment Status According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist
Unknown
|
32 Participants
|
19 Participants
|
3 Participants
|
7 Participants
|
—
|
SECONDARY outcome
Timeframe: At study index date 1 (i.e. between September 2018 and December 2018).Population: Patients of the prescribed patient set (PPS) who were initiated on type 2 diabetes (T2D) medication by endocrinologist. PPS included all patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective T2D medication and whose documentation was electronically signed by the physician.
Number of patients in each category of family status according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by endocrinologist is reported. The categories of family status are: * Single * Married * Divorced * Widowed * Unknown
Outcome measures
| Measure |
Patients Initiated on T2D Medication by Endocrinologist
n=815 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by endocrinologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Diabetologist
n=504 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by diabetologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Cardiologist
n=89 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by cardiologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on Other SGLT2i by Endocrinologist
n=244 Participants
Patients with type 2 diabetes from Central Eastern Europe (CEE) (i.e. Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who have been newly initiated (first ever use) on other sodium dependent glucose transporter inhibitor (SGLT2i) between September 2018 and December 2018 (study index date 1) by endocrinologist.
|
T2D Patients From Russian Federation
Patients with type 2 diabetes (T2D) from Russian Federation who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) between September 2018 and December 2018 (study index date 1) and have consented to documentation at study index date 2.
|
|---|---|---|---|---|---|
|
Number of Patients in Each Category of Family Status According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist
Single
|
55 Participants
|
52 Participants
|
7 Participants
|
22 Participants
|
—
|
|
Number of Patients in Each Category of Family Status According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist
Married
|
566 Participants
|
290 Participants
|
68 Participants
|
175 Participants
|
—
|
|
Number of Patients in Each Category of Family Status According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist
Divorced
|
44 Participants
|
27 Participants
|
5 Participants
|
6 Participants
|
—
|
|
Number of Patients in Each Category of Family Status According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist
Widowed
|
67 Participants
|
69 Participants
|
2 Participants
|
9 Participants
|
—
|
|
Number of Patients in Each Category of Family Status According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist
Unknown
|
83 Participants
|
66 Participants
|
7 Participants
|
32 Participants
|
—
|
SECONDARY outcome
Timeframe: At study index date 1 (i.e. between September 2018 and December 2018).Population: Patients of the prescribed patient set (PPS) who were initiated on type 2 diabetes (T2D) medication by endocrinologist. PPS included all patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective T2D medication and whose documentation was electronically signed by the physician.
Number of patients in each category of insurance status according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by endocrinologist is reported. The categories of insurance status are: * Not insured * Statutory insured * Privately insured * Unknown
Outcome measures
| Measure |
Patients Initiated on T2D Medication by Endocrinologist
n=815 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by endocrinologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Diabetologist
n=504 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by diabetologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Cardiologist
n=89 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by cardiologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on Other SGLT2i by Endocrinologist
n=244 Participants
Patients with type 2 diabetes from Central Eastern Europe (CEE) (i.e. Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who have been newly initiated (first ever use) on other sodium dependent glucose transporter inhibitor (SGLT2i) between September 2018 and December 2018 (study index date 1) by endocrinologist.
|
T2D Patients From Russian Federation
Patients with type 2 diabetes (T2D) from Russian Federation who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) between September 2018 and December 2018 (study index date 1) and have consented to documentation at study index date 2.
|
|---|---|---|---|---|---|
|
Number of Patients in Each Category of Insurance Status According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist
Not insured
|
40 Participants
|
12 Participants
|
3 Participants
|
11 Participants
|
—
|
|
Number of Patients in Each Category of Insurance Status According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist
Statutory insured
|
630 Participants
|
438 Participants
|
73 Participants
|
208 Participants
|
—
|
|
Number of Patients in Each Category of Insurance Status According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist
Privately insured
|
82 Participants
|
34 Participants
|
13 Participants
|
16 Participants
|
—
|
|
Number of Patients in Each Category of Insurance Status According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist
Unknown
|
63 Participants
|
20 Participants
|
0.0 Participants
|
9 Participants
|
—
|
SECONDARY outcome
Timeframe: At study index date 1 (i.e. between September 2018 and December 2018).Population: Patients of the prescribed patient set (PPS) who were initiated on type 2 diabetes (T2D) medication by diabetologist. PPS included all patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective T2D medication and whose documentation was electronically signed by the physician.
Number of patients in each category of employment status according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by diabetologist is reported. The categories of employment status are: * Employed * Not employed * Unknown
Outcome measures
| Measure |
Patients Initiated on T2D Medication by Endocrinologist
n=1073 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by endocrinologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Diabetologist
n=624 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by diabetologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Cardiologist
n=271 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by cardiologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on Other SGLT2i by Endocrinologist
n=333 Participants
Patients with type 2 diabetes from Central Eastern Europe (CEE) (i.e. Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who have been newly initiated (first ever use) on other sodium dependent glucose transporter inhibitor (SGLT2i) between September 2018 and December 2018 (study index date 1) by endocrinologist.
|
T2D Patients From Russian Federation
Patients with type 2 diabetes (T2D) from Russian Federation who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) between September 2018 and December 2018 (study index date 1) and have consented to documentation at study index date 2.
|
|---|---|---|---|---|---|
|
Number of Patients in Each Category of Employment Status According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist
Employed
|
491 Participants
|
228 Participants
|
159 Participants
|
171 Participants
|
—
|
|
Number of Patients in Each Category of Employment Status According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist
Not employed
|
500 Participants
|
345 Participants
|
94 Participants
|
150 Participants
|
—
|
|
Number of Patients in Each Category of Employment Status According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist
Unknown
|
82 Participants
|
51 Participants
|
18 Participants
|
12 Participants
|
—
|
SECONDARY outcome
Timeframe: At study index date 1 (i.e. between September 2018 and December 2018).Population: Patients of the prescribed patient set (PPS) who were initiated on type 2 diabetes (T2D) medication by diabetologist. PPS included all patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective T2D medication and whose documentation was electronically signed by the physician.
Number of patients in each category of family status according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by diabetologist is reported. The categories of family status are: * Single * Married * Divorced * Widowed * Unknown
Outcome measures
| Measure |
Patients Initiated on T2D Medication by Endocrinologist
n=1073 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by endocrinologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Diabetologist
n=624 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by diabetologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Cardiologist
n=271 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by cardiologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on Other SGLT2i by Endocrinologist
n=333 Participants
Patients with type 2 diabetes from Central Eastern Europe (CEE) (i.e. Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who have been newly initiated (first ever use) on other sodium dependent glucose transporter inhibitor (SGLT2i) between September 2018 and December 2018 (study index date 1) by endocrinologist.
|
T2D Patients From Russian Federation
Patients with type 2 diabetes (T2D) from Russian Federation who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) between September 2018 and December 2018 (study index date 1) and have consented to documentation at study index date 2.
|
|---|---|---|---|---|---|
|
Number of Patients in Each Category of Family Status According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist
Unknown
|
181 Participants
|
116 Participants
|
30 Participants
|
29 Participants
|
—
|
|
Number of Patients in Each Category of Family Status According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist
Single
|
56 Participants
|
33 Participants
|
19 Participants
|
19 Participants
|
—
|
|
Number of Patients in Each Category of Family Status According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist
Married
|
727 Participants
|
368 Participants
|
183 Participants
|
233 Participants
|
—
|
|
Number of Patients in Each Category of Family Status According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist
Divorced
|
38 Participants
|
31 Participants
|
22 Participants
|
31 Participants
|
—
|
|
Number of Patients in Each Category of Family Status According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist
Widowed
|
71 Participants
|
76 Participants
|
17 Participants
|
21 Participants
|
—
|
SECONDARY outcome
Timeframe: At study index date 1 (i.e. between September 2018 and December 2018).Population: Patients of the prescribed patient set (PPS) who were initiated on type 2 diabetes (T2D) medication by diabetologist. PPS included all patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective T2D medication and whose documentation was electronically signed by the physician..
Number of patients in each category of insurance status according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by diabetologist is reported. The categories of insurance status are: * Not insured * Statutory insured * Privately insured * Unknown
Outcome measures
| Measure |
Patients Initiated on T2D Medication by Endocrinologist
n=1073 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by endocrinologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Diabetologist
n=624 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by diabetologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Cardiologist
n=271 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by cardiologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on Other SGLT2i by Endocrinologist
n=333 Participants
Patients with type 2 diabetes from Central Eastern Europe (CEE) (i.e. Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who have been newly initiated (first ever use) on other sodium dependent glucose transporter inhibitor (SGLT2i) between September 2018 and December 2018 (study index date 1) by endocrinologist.
|
T2D Patients From Russian Federation
Patients with type 2 diabetes (T2D) from Russian Federation who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) between September 2018 and December 2018 (study index date 1) and have consented to documentation at study index date 2.
|
|---|---|---|---|---|---|
|
Number of Patients in Each Category of Insurance Status According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist
Unknown
|
29 Participants
|
19 Participants
|
9 Participants
|
7 Participants
|
—
|
|
Number of Patients in Each Category of Insurance Status According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist
Not insured
|
2 Participants
|
1 Participants
|
0.0 Participants
|
0.0 Participants
|
—
|
|
Number of Patients in Each Category of Insurance Status According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist
Statutory insured
|
1039 Participants
|
603 Participants
|
262 Participants
|
326 Participants
|
—
|
|
Number of Patients in Each Category of Insurance Status According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist
Privately insured
|
3 Participants
|
1 Participants
|
0.0 Participants
|
0 Participants
|
—
|
SECONDARY outcome
Timeframe: At study index date 1 (i.e. between September 2018 and December 2018).Population: Patients of the prescribed patient set (PPS) who were initiated on type 2 diabetes (T2D) medication by cardiologist. PPS included all patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective T2D medication and whose documentation was electronically signed by the physician.
Number of patients in each category of employment status according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by cardiologist is reported. The categories of employment status are: * Employed * Not employed * Unknown
Outcome measures
| Measure |
Patients Initiated on T2D Medication by Endocrinologist
n=78 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by endocrinologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Diabetologist
n=16 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by diabetologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Cardiologist
n=1 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by cardiologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on Other SGLT2i by Endocrinologist
n=7 Participants
Patients with type 2 diabetes from Central Eastern Europe (CEE) (i.e. Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who have been newly initiated (first ever use) on other sodium dependent glucose transporter inhibitor (SGLT2i) between September 2018 and December 2018 (study index date 1) by endocrinologist.
|
T2D Patients From Russian Federation
Patients with type 2 diabetes (T2D) from Russian Federation who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) between September 2018 and December 2018 (study index date 1) and have consented to documentation at study index date 2.
|
|---|---|---|---|---|---|
|
Number of Patients in Each Category of Employment Status According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist
Employed
|
37 Participants
|
6 Participants
|
1 Participants
|
3 Participants
|
—
|
|
Number of Patients in Each Category of Employment Status According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist
Not employed
|
33 Participants
|
8 Participants
|
0 Participants
|
2 Participants
|
—
|
|
Number of Patients in Each Category of Employment Status According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist
Unknown
|
8 Participants
|
2 Participants
|
0 Participants
|
2 Participants
|
—
|
SECONDARY outcome
Timeframe: At study index date 1 (i.e. between September 2018 and December 2018).Population: Patients of the prescribed patient set (PPS) who were initiated on type 2 diabetes (T2D) medication by cardiologist. PPS included all patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective T2D medication and whose documentation was electronically signed by the physician.
Number of patients in each category of family status according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by cardiologist is reported. The categories of family status are: * Single * Married * Divorced * Widowed * Unknown
Outcome measures
| Measure |
Patients Initiated on T2D Medication by Endocrinologist
n=78 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by endocrinologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Diabetologist
n=16 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by diabetologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Cardiologist
n=1 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by cardiologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on Other SGLT2i by Endocrinologist
n=7 Participants
Patients with type 2 diabetes from Central Eastern Europe (CEE) (i.e. Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who have been newly initiated (first ever use) on other sodium dependent glucose transporter inhibitor (SGLT2i) between September 2018 and December 2018 (study index date 1) by endocrinologist.
|
T2D Patients From Russian Federation
Patients with type 2 diabetes (T2D) from Russian Federation who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) between September 2018 and December 2018 (study index date 1) and have consented to documentation at study index date 2.
|
|---|---|---|---|---|---|
|
Number of Patients in Each Category of Family Status According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist
Single
|
13 Participants
|
1 Participants
|
0 Participants
|
1 Participants
|
—
|
|
Number of Patients in Each Category of Family Status According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist
Married
|
46 Participants
|
10 Participants
|
1 Participants
|
3 Participants
|
—
|
|
Number of Patients in Each Category of Family Status According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist
Divorced
|
6 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
—
|
|
Number of Patients in Each Category of Family Status According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist
Widowed
|
5 Participants
|
2 Participants
|
0 Participants
|
1 Participants
|
—
|
|
Number of Patients in Each Category of Family Status According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist
Unknown
|
8 Participants
|
2 Participants
|
0 Participants
|
2 Participants
|
—
|
SECONDARY outcome
Timeframe: At study index date 1 (i.e. between September 2018 and December 2018).Population: Patients of the prescribed patient set (PPS) who were initiated on type 2 diabetes (T2D) medication by cardiologist. PPS included all patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective T2D medication and whose documentation was electronically signed by the physician.
Number of patients in each category of insurance status according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by cardiologist is reported. The categories of insurance status are: * Not insured * Statutory insured * Privately insured * Unknown
Outcome measures
| Measure |
Patients Initiated on T2D Medication by Endocrinologist
n=78 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by endocrinologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Diabetologist
n=16 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by diabetologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Cardiologist
n=1 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by cardiologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on Other SGLT2i by Endocrinologist
n=7 Participants
Patients with type 2 diabetes from Central Eastern Europe (CEE) (i.e. Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who have been newly initiated (first ever use) on other sodium dependent glucose transporter inhibitor (SGLT2i) between September 2018 and December 2018 (study index date 1) by endocrinologist.
|
T2D Patients From Russian Federation
Patients with type 2 diabetes (T2D) from Russian Federation who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) between September 2018 and December 2018 (study index date 1) and have consented to documentation at study index date 2.
|
|---|---|---|---|---|---|
|
Number of Patients in Each Category of Insurance Status According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist
Not insured
|
8 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
—
|
|
Number of Patients in Each Category of Insurance Status According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist
Statutory insured
|
56 Participants
|
14 Participants
|
1 Participants
|
5 Participants
|
—
|
|
Number of Patients in Each Category of Insurance Status According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist
Privately insured
|
4 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
—
|
|
Number of Patients in Each Category of Insurance Status According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist
Unknown
|
10 Participants
|
2 Participants
|
0 Participants
|
2 Participants
|
—
|
SECONDARY outcome
Timeframe: At study index date 2 (= one year ± 2 months after index date 1 (study index date 1 was between September 2018 and December 2018)).Population: Full Analysis set (FAS): All patients from Prescribed patient Set (PPS) with documentation at index date 2 and whose documentation was electronically signed by the physician. Patients included before the protocol amendment needed an additional signed informed consent at index date 2.
Number of patients in each category of status of type 2 diabetes (T2D) medication at index date 2 according to type 2 diabetes (T2D) medication initiated at study index date 1 is reported. The categories of status of T2D medication are: * Discontinued * Continued
Outcome measures
| Measure |
Patients Initiated on T2D Medication by Endocrinologist
n=1697 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by endocrinologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Diabetologist
n=1053 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by diabetologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Cardiologist
n=332 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by cardiologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on Other SGLT2i by Endocrinologist
n=536 Participants
Patients with type 2 diabetes from Central Eastern Europe (CEE) (i.e. Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who have been newly initiated (first ever use) on other sodium dependent glucose transporter inhibitor (SGLT2i) between September 2018 and December 2018 (study index date 1) by endocrinologist.
|
T2D Patients From Russian Federation
Patients with type 2 diabetes (T2D) from Russian Federation who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) between September 2018 and December 2018 (study index date 1) and have consented to documentation at study index date 2.
|
|---|---|---|---|---|---|
|
Number of Patients in Each Category of Status of Type 2 Diabetes (T2D) Medication at Index Date 2 According to Type 2 Diabetes (T2D) Medication Initiated at Study Index Date 1
Discontinued
|
134 Participants
|
129 Participants
|
38 Participants
|
60 Participants
|
—
|
|
Number of Patients in Each Category of Status of Type 2 Diabetes (T2D) Medication at Index Date 2 According to Type 2 Diabetes (T2D) Medication Initiated at Study Index Date 1
Continued
|
1563 Participants
|
924 Participants
|
294 Participants
|
476 Participants
|
—
|
SECONDARY outcome
Timeframe: At study index date 2 (= one year ± 2 months after index date 1 (study index date 1 was between September 2018 and December 2018)).Population: Patients of the full analysis set (FAS) who were initiated on type 2 diabetes (T2D) medication by endocrinologist. FAS included all patients from the prescribed patient set (PPS) with documentation at index date 2 and whose documentation was electronically signed by the physician. Patients included before the protocol amendment needed an additional signed informed consent at index date 2.
Number of patients in each category of status of type 2 diabetes (T2D) medication at index date 2 according to T2D medication for the patients who were initiated on T2D medication by endocrinologist is reported. The categories of status of T2D medication are: * Discontinued * Continued
Outcome measures
| Measure |
Patients Initiated on T2D Medication by Endocrinologist
n=731 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by endocrinologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Diabetologist
n=479 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by diabetologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Cardiologist
n=81 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by cardiologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on Other SGLT2i by Endocrinologist
n=214 Participants
Patients with type 2 diabetes from Central Eastern Europe (CEE) (i.e. Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who have been newly initiated (first ever use) on other sodium dependent glucose transporter inhibitor (SGLT2i) between September 2018 and December 2018 (study index date 1) by endocrinologist.
|
T2D Patients From Russian Federation
Patients with type 2 diabetes (T2D) from Russian Federation who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) between September 2018 and December 2018 (study index date 1) and have consented to documentation at study index date 2.
|
|---|---|---|---|---|---|
|
Number of Patients in Each Category of Status of Type 2 Diabetes (T2D) Medication at Index Date 2 According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist
Discontinued
|
42 Participants
|
58 Participants
|
17 Participants
|
26 Participants
|
—
|
|
Number of Patients in Each Category of Status of Type 2 Diabetes (T2D) Medication at Index Date 2 According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist
Continued
|
689 Participants
|
421 Participants
|
64 Participants
|
188 Participants
|
—
|
SECONDARY outcome
Timeframe: At study index date 2 (= one year ± 2 months after index date 1 (study index date 1 was between September 2018 and December 2018)).Population: Patients of the full analysis set (FAS) who were initiated on type 2 diabetes (T2D) medication by diabetologist. FAS included all patients from the prescribed patient set (PPS) with documentation at index date 2 and whose documentation was electronically signed by the physician. Patients included before the protocol amendment needed an additional signed informed consent at index date 2.
Number of patients in each category of status of type 2 diabetes (T2D) medication at index date 2 according to T2D medication for the patients who were initiated on T2D medication by diabetologist is reported. The categories of status of T2D medication are: * Discontinued * Continued
Outcome measures
| Measure |
Patients Initiated on T2D Medication by Endocrinologist
n=906 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by endocrinologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Diabetologist
n=561 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by diabetologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Cardiologist
n=250 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by cardiologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on Other SGLT2i by Endocrinologist
n=316 Participants
Patients with type 2 diabetes from Central Eastern Europe (CEE) (i.e. Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who have been newly initiated (first ever use) on other sodium dependent glucose transporter inhibitor (SGLT2i) between September 2018 and December 2018 (study index date 1) by endocrinologist.
|
T2D Patients From Russian Federation
Patients with type 2 diabetes (T2D) from Russian Federation who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) between September 2018 and December 2018 (study index date 1) and have consented to documentation at study index date 2.
|
|---|---|---|---|---|---|
|
Number of Patients in Each Category of Status of Type 2 Diabetes (T2D) Medication at Index Date 2 According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist
Discontinued
|
87 Participants
|
71 Participants
|
21 Participants
|
34 Participants
|
—
|
|
Number of Patients in Each Category of Status of Type 2 Diabetes (T2D) Medication at Index Date 2 According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist
Continued
|
819 Participants
|
490 Participants
|
229 Participants
|
282 Participants
|
—
|
SECONDARY outcome
Timeframe: At study index date 2 (= one year ± 2 months after index date 1 (study index date 1 was between September 2018 and December 2018)).Population: Patients of the full analysis set (FAS) who were initiated on type 2 diabetes (T2D) medication by cardiologist. FAS included all patients from the prescribed patient set (PPS) with documentation at index date 2 and whose documentation was electronically signed by the physician. Patients included before the protocol amendment needed an additional signed informed consent at index date 2.
Number of patients in each category of status of type 2 diabetes (T2D) medication at index date 2 according to T2D medication for the patients who were initiated on T2D medication by cardiologist is reported. The categories of status of T2D medication are: * Discontinued * Continued
Outcome measures
| Measure |
Patients Initiated on T2D Medication by Endocrinologist
n=60 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by endocrinologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Diabetologist
n=13 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by diabetologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Cardiologist
n=1 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by cardiologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on Other SGLT2i by Endocrinologist
n=6 Participants
Patients with type 2 diabetes from Central Eastern Europe (CEE) (i.e. Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who have been newly initiated (first ever use) on other sodium dependent glucose transporter inhibitor (SGLT2i) between September 2018 and December 2018 (study index date 1) by endocrinologist.
|
T2D Patients From Russian Federation
Patients with type 2 diabetes (T2D) from Russian Federation who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) between September 2018 and December 2018 (study index date 1) and have consented to documentation at study index date 2.
|
|---|---|---|---|---|---|
|
Number of Patients in Each Category of Status of Type 2 Diabetes (T2D) Medication at Index Date 2 According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist
Discontinued
|
5 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
—
|
|
Number of Patients in Each Category of Status of Type 2 Diabetes (T2D) Medication at Index Date 2 According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist
Continued
|
55 Participants
|
13 Participants
|
1 Participants
|
6 Participants
|
—
|
SECONDARY outcome
Timeframe: At study index date 2 (= one year ± 2 months after index date 1 (study index date 1 was between September 2018 and December 2018)).Population: Patients in the full analysis set (FAS) who discontinued the study medication. FAS included all patients from the prescribed patient set (PPS) with documentation at index date 2 and whose documentation was electronically signed by the physician. Patients included before the protocol amendment needed an additional signed informed consent at index date 2.
Number of patients in each category of reason for discontinuation of type 2 diabetes (T2D) medication by country is reported. The categories of reason for discontinuation of T2D medication are: * Lack of efficacy * Medication administration * Financial burden regarding co-payment * Lost to follow-up * Adverse event * Other
Outcome measures
| Measure |
Patients Initiated on T2D Medication by Endocrinologist
n=25 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by endocrinologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Diabetologist
n=90 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by diabetologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Cardiologist
n=16 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by cardiologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on Other SGLT2i by Endocrinologist
n=104 Participants
Patients with type 2 diabetes from Central Eastern Europe (CEE) (i.e. Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who have been newly initiated (first ever use) on other sodium dependent glucose transporter inhibitor (SGLT2i) between September 2018 and December 2018 (study index date 1) by endocrinologist.
|
T2D Patients From Russian Federation
n=126 Participants
Patients with type 2 diabetes (T2D) from Russian Federation who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) between September 2018 and December 2018 (study index date 1) and have consented to documentation at study index date 2.
|
|---|---|---|---|---|---|
|
Number of Patients in Each Category of Reason for Discontinuation of Type 2 Diabetes (T2D) Medication by Country
Other
|
2 Participants
|
13 Participants
|
3 Participants
|
2 Participants
|
12 Participants
|
|
Number of Patients in Each Category of Reason for Discontinuation of Type 2 Diabetes (T2D) Medication by Country
Financial burden regarding co-payment
|
2 Participants
|
0 Participants
|
2 Participants
|
58 Participants
|
60 Participants
|
|
Number of Patients in Each Category of Reason for Discontinuation of Type 2 Diabetes (T2D) Medication by Country
Lost to follow-up
|
0 Participants
|
3 Participants
|
1 Participants
|
5 Participants
|
1 Participants
|
|
Number of Patients in Each Category of Reason for Discontinuation of Type 2 Diabetes (T2D) Medication by Country
Lack of efficacy
|
17 Participants
|
64 Participants
|
9 Participants
|
15 Participants
|
30 Participants
|
|
Number of Patients in Each Category of Reason for Discontinuation of Type 2 Diabetes (T2D) Medication by Country
Medication administration
|
1 Participants
|
1 Participants
|
0 Participants
|
1 Participants
|
16 Participants
|
|
Number of Patients in Each Category of Reason for Discontinuation of Type 2 Diabetes (T2D) Medication by Country
Adverse event
|
3 Participants
|
9 Participants
|
1 Participants
|
23 Participants
|
7 Participants
|
SECONDARY outcome
Timeframe: At study index date 2 (= one year ± 2 months after index date 1 (study index date 1 was between September 2018 and December 2018)).Population: Patients in the full analysis set (FAS) who discontinued the study medication. FAS included all patients from the prescribed patient set (PPS) with documentation at index date 2 and whose documentation was electronically signed by the physician. Patients included before the protocol amendment needed an additional signed informed consent at index date 2.
Number of patients in each category of reason for discontinuation of type 2 diabetes (T2D) medication according to type 2 diabetes (T2D) medication initiated at study index date 1 is reported. The categories of reason for discontinuation of T2D medication are: * Lack of efficacy * Medication administration * Financial burden regarding co-payment * Lost to follow-up * Adverse event * Other
Outcome measures
| Measure |
Patients Initiated on T2D Medication by Endocrinologist
n=134 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by endocrinologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Diabetologist
n=129 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by diabetologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Cardiologist
n=38 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by cardiologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on Other SGLT2i by Endocrinologist
n=60 Participants
Patients with type 2 diabetes from Central Eastern Europe (CEE) (i.e. Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who have been newly initiated (first ever use) on other sodium dependent glucose transporter inhibitor (SGLT2i) between September 2018 and December 2018 (study index date 1) by endocrinologist.
|
T2D Patients From Russian Federation
Patients with type 2 diabetes (T2D) from Russian Federation who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) between September 2018 and December 2018 (study index date 1) and have consented to documentation at study index date 2.
|
|---|---|---|---|---|---|
|
Number of Patients in Each Category of Reason for Discontinuation of Type 2 Diabetes (T2D) Medication According to Type 2 Diabetes (T2D) Medication Initiated at Study Index Date 1
Lack of efficacy
|
29 Participants
|
67 Participants
|
20 Participants
|
19 Participants
|
—
|
|
Number of Patients in Each Category of Reason for Discontinuation of Type 2 Diabetes (T2D) Medication According to Type 2 Diabetes (T2D) Medication Initiated at Study Index Date 1
Medication administration
|
8 Participants
|
7 Participants
|
1 Participants
|
3 Participants
|
—
|
|
Number of Patients in Each Category of Reason for Discontinuation of Type 2 Diabetes (T2D) Medication According to Type 2 Diabetes (T2D) Medication Initiated at Study Index Date 1
Financial burden regarding co-payment
|
49 Participants
|
37 Participants
|
9 Participants
|
27 Participants
|
—
|
|
Number of Patients in Each Category of Reason for Discontinuation of Type 2 Diabetes (T2D) Medication According to Type 2 Diabetes (T2D) Medication Initiated at Study Index Date 1
Lost to follow-up
|
5 Participants
|
3 Participants
|
0 Participants
|
2 Participants
|
—
|
|
Number of Patients in Each Category of Reason for Discontinuation of Type 2 Diabetes (T2D) Medication According to Type 2 Diabetes (T2D) Medication Initiated at Study Index Date 1
Adverse event
|
32 Participants
|
0 Participants
|
3 Participants
|
8 Participants
|
—
|
|
Number of Patients in Each Category of Reason for Discontinuation of Type 2 Diabetes (T2D) Medication According to Type 2 Diabetes (T2D) Medication Initiated at Study Index Date 1
Other
|
11 Participants
|
15 Participants
|
5 Participants
|
1 Participants
|
—
|
SECONDARY outcome
Timeframe: At study index date 2 (= one year ± 2 months after index date 1 (study index date 1 was between September 2018 and December 2018)).Population: Patients in the full analysis set (FAS) who discontinued the study medication and who were initiated on type 2 diabetes (T2D) medication by endocrinologist. FAS included all patients from the prescribed patient set (PPS) with documentation at index date 2 and whose documentation was electronically signed by the physician. Patients included before the protocol amendment needed an additional signed informed consent at index date 2.
Number of patients in each category of reason for discontinuation of type 2 diabetes (T2D) according to T2D medication for the patients who were initiated on T2D medication by endocrinologist is reported. The categories of reason for discontinuation of T2D medication are: * Lack of efficacy * Medication administration * Financial burden regarding co-payment * Lost to follow-up * Adverse event * Other
Outcome measures
| Measure |
Patients Initiated on T2D Medication by Endocrinologist
n=42 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by endocrinologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Diabetologist
n=58 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by diabetologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Cardiologist
n=17 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by cardiologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on Other SGLT2i by Endocrinologist
n=26 Participants
Patients with type 2 diabetes from Central Eastern Europe (CEE) (i.e. Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who have been newly initiated (first ever use) on other sodium dependent glucose transporter inhibitor (SGLT2i) between September 2018 and December 2018 (study index date 1) by endocrinologist.
|
T2D Patients From Russian Federation
Patients with type 2 diabetes (T2D) from Russian Federation who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) between September 2018 and December 2018 (study index date 1) and have consented to documentation at study index date 2.
|
|---|---|---|---|---|---|
|
Number of Patients in Each Category of Reason for Discontinuation of Type 2 Diabetes (T2D) According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist
Other
|
8 Participants
|
2 Participants
|
2 Participants
|
1 Participants
|
—
|
|
Number of Patients in Each Category of Reason for Discontinuation of Type 2 Diabetes (T2D) According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist
Financial burden regarding co-payment
|
15 Participants
|
24 Participants
|
7 Participants
|
14 Participants
|
—
|
|
Number of Patients in Each Category of Reason for Discontinuation of Type 2 Diabetes (T2D) According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist
Lost to follow-up
|
1 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
—
|
|
Number of Patients in Each Category of Reason for Discontinuation of Type 2 Diabetes (T2D) According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist
Adverse event
|
2 Participants
|
0 Participants
|
2 Participants
|
6 Participants
|
—
|
|
Number of Patients in Each Category of Reason for Discontinuation of Type 2 Diabetes (T2D) According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist
Lack of efficacy
|
10 Participants
|
26 Participants
|
6 Participants
|
2 Participants
|
—
|
|
Number of Patients in Each Category of Reason for Discontinuation of Type 2 Diabetes (T2D) According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist
Medication administration
|
6 Participants
|
6 Participants
|
0 Participants
|
3 Participants
|
—
|
SECONDARY outcome
Timeframe: At study index date 2 (= one year ± 2 months after index date 1 (study index date 1 was between September 2018 and December 2018)).Population: Patients in the full analysis set (FAS) who discontinued the study medication and who were initiated on type 2 diabetes (T2D) medication by diabetologist. FAS included all patients from the prescribed patient set (PPS) with documentation at index date 2 and whose documentation was electronically signed by the physician. Patients included before the protocol amendment needed an additional signed informed consent at index date 2.
Number of patients in each category of reason for discontinuation of type 2 diabetes (T2D) medication according to T2D medication for the patients who were initiated on T2D medication by diabetologist is reported. The categories of reason for discontinuation of T2D medication are: * Lack of efficacy * Medication administration * Financial burden regarding co-payment * Lost to follow-up * Adverse event * Other
Outcome measures
| Measure |
Patients Initiated on T2D Medication by Endocrinologist
n=87 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by endocrinologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Diabetologist
n=71 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by diabetologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Cardiologist
n=21 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by cardiologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on Other SGLT2i by Endocrinologist
n=34 Participants
Patients with type 2 diabetes from Central Eastern Europe (CEE) (i.e. Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who have been newly initiated (first ever use) on other sodium dependent glucose transporter inhibitor (SGLT2i) between September 2018 and December 2018 (study index date 1) by endocrinologist.
|
T2D Patients From Russian Federation
Patients with type 2 diabetes (T2D) from Russian Federation who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) between September 2018 and December 2018 (study index date 1) and have consented to documentation at study index date 2.
|
|---|---|---|---|---|---|
|
Number of Patients in Each Category of Reason for Discontinuation of Type 2 Diabetes (T2D) Medication According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist
Lack of efficacy
|
17 Participants
|
41 Participants
|
14 Participants
|
17 Participants
|
—
|
|
Number of Patients in Each Category of Reason for Discontinuation of Type 2 Diabetes (T2D) Medication According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist
Medication administration
|
0 Participants
|
1 Participants
|
1 Participants
|
0 Participants
|
—
|
|
Number of Patients in Each Category of Reason for Discontinuation of Type 2 Diabetes (T2D) Medication According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist
Financial burden regarding co-payment
|
34 Participants
|
13 Participants
|
2 Participants
|
13 Participants
|
—
|
|
Number of Patients in Each Category of Reason for Discontinuation of Type 2 Diabetes (T2D) Medication According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist
Lost to follow-up
|
4 Participants
|
3 Participants
|
0 Participants
|
2 Participants
|
—
|
|
Number of Patients in Each Category of Reason for Discontinuation of Type 2 Diabetes (T2D) Medication According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist
Adverse event
|
30 Participants
|
0 Participants
|
1 Participants
|
2 Participants
|
—
|
|
Number of Patients in Each Category of Reason for Discontinuation of Type 2 Diabetes (T2D) Medication According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist
Other
|
2 Participants
|
13 Participants
|
3 Participants
|
0 Participants
|
—
|
SECONDARY outcome
Timeframe: At study index date 2 (= one year ± 2 months after index date 1 (study index date 1 was between September 2018 and December 2018)).Population: Patients in the full analysis set (FAS) who discontinued the study medication and who were initiated on type 2 diabetes (T2D) medication by cardiologist. FAS included all patients from the prescribed patient set (PPS) with documentation at index date 2 and whose documentation was electronically signed by the physician. Patients included before the protocol amendment needed an additional signed informed consent at index date 2.
Number of patients in each category of reason for discontinuation of type 2 diabetes (T2D) medication according to T2D medication for the patients who were initiated on T2D medication by cardiologist is reported. The categories of reason for discontinuation of T2D medication are: * Lack of efficacy * Medication administration * Financial burden regarding co-payment * Lost to follow-up * Adverse event * Other
Outcome measures
| Measure |
Patients Initiated on T2D Medication by Endocrinologist
n=5 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by endocrinologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Diabetologist
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by diabetologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Cardiologist
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by cardiologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on Other SGLT2i by Endocrinologist
Patients with type 2 diabetes from Central Eastern Europe (CEE) (i.e. Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who have been newly initiated (first ever use) on other sodium dependent glucose transporter inhibitor (SGLT2i) between September 2018 and December 2018 (study index date 1) by endocrinologist.
|
T2D Patients From Russian Federation
Patients with type 2 diabetes (T2D) from Russian Federation who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) between September 2018 and December 2018 (study index date 1) and have consented to documentation at study index date 2.
|
|---|---|---|---|---|---|
|
Number of Patients in Each Category of Reason for Discontinuation of Type 2 Diabetes (T2D) Medication According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist
Lack of efficacy
|
2 Participants
|
—
|
—
|
—
|
—
|
|
Number of Patients in Each Category of Reason for Discontinuation of Type 2 Diabetes (T2D) Medication According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist
Medication administration
|
2 Participants
|
—
|
—
|
—
|
—
|
|
Number of Patients in Each Category of Reason for Discontinuation of Type 2 Diabetes (T2D) Medication According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist
Financial burden regarding co-payment
|
0 Participants
|
—
|
—
|
—
|
—
|
|
Number of Patients in Each Category of Reason for Discontinuation of Type 2 Diabetes (T2D) Medication According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist
Lost to follow-up
|
0 Participants
|
—
|
—
|
—
|
—
|
|
Number of Patients in Each Category of Reason for Discontinuation of Type 2 Diabetes (T2D) Medication According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist
Adverse event
|
0 Participants
|
—
|
—
|
—
|
—
|
|
Number of Patients in Each Category of Reason for Discontinuation of Type 2 Diabetes (T2D) Medication According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist
Other
|
1 Participants
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: At study index date 2 (= one year ± 2 months after index date 1 (study index date 1 was between September 2018 and December 2018)).Population: Patients in the full analysis set (FAS) who discontinued the study medication. FAS included all patients from the prescribed patient set (PPS) with documentation at index date 2 and whose documentation was electronically signed by the physician. Patients included before the protocol amendment needed an additional signed informed consent at index date 2.
Number of patients for each type of physician specialties involved in decision for T2D therapy discontinuation according to prescribing specialist is reported.
Outcome measures
| Measure |
Patients Initiated on T2D Medication by Endocrinologist
n=143 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by endocrinologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Diabetologist
n=213 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by diabetologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Cardiologist
n=5 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by cardiologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on Other SGLT2i by Endocrinologist
Patients with type 2 diabetes from Central Eastern Europe (CEE) (i.e. Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who have been newly initiated (first ever use) on other sodium dependent glucose transporter inhibitor (SGLT2i) between September 2018 and December 2018 (study index date 1) by endocrinologist.
|
T2D Patients From Russian Federation
Patients with type 2 diabetes (T2D) from Russian Federation who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) between September 2018 and December 2018 (study index date 1) and have consented to documentation at study index date 2.
|
|---|---|---|---|---|---|
|
Number of Patients for Each Type of Physician Specialties Involved in Decision for T2D Therapy Discontinuation According to Prescribing Specialist
Endocrinologist
|
26 Participants
|
0 Participants
|
4 Participants
|
—
|
—
|
|
Number of Patients for Each Type of Physician Specialties Involved in Decision for T2D Therapy Discontinuation According to Prescribing Specialist
Diabetologist
|
0 Participants
|
2 Participants
|
0 Participants
|
—
|
—
|
|
Number of Patients for Each Type of Physician Specialties Involved in Decision for T2D Therapy Discontinuation According to Prescribing Specialist
Cardiologist
|
2 Participants
|
0 Participants
|
0 Participants
|
—
|
—
|
|
Number of Patients for Each Type of Physician Specialties Involved in Decision for T2D Therapy Discontinuation According to Prescribing Specialist
General practitioner
|
14 Participants
|
23 Participants
|
1 Participants
|
—
|
—
|
|
Number of Patients for Each Type of Physician Specialties Involved in Decision for T2D Therapy Discontinuation According to Prescribing Specialist
Other
|
2 Participants
|
3 Participants
|
0 Participants
|
—
|
—
|
|
Number of Patients for Each Type of Physician Specialties Involved in Decision for T2D Therapy Discontinuation According to Prescribing Specialist
None
|
102 Participants
|
185 Participants
|
0 Participants
|
—
|
—
|
SECONDARY outcome
Timeframe: From date of first prescription (study index date 1) to stop date of initial type 2 diabetes (T2D)) medication (documented at index date 2), up to 14 months..Population: Full Analysis set (FAS): All patients from prescribed patient Set (PPS) with documentation at index date 2 and whose documentation was electronically signed by the physician. Patients included before the protocol amendment needed an additional signed informed consent at index date 2.
Time to discontinuation of type 2 diabetes (T2D) treatment according to study medication is reported. Time to discontinuation of T2D medication was estimated by Kaplan-Meier analysis. Patients who did not discontinue study medication at study index date 2 were censored.
Outcome measures
| Measure |
Patients Initiated on T2D Medication by Endocrinologist
n=1697 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by endocrinologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Diabetologist
n=1053 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by diabetologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on T2D Medication by Cardiologist
n=332 Participants
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) by cardiologist between September 2018 and December 2018 (study index date 1).
|
Patients Initiated on Other SGLT2i by Endocrinologist
n=536 Participants
Patients with type 2 diabetes from Central Eastern Europe (CEE) (i.e. Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who have been newly initiated (first ever use) on other sodium dependent glucose transporter inhibitor (SGLT2i) between September 2018 and December 2018 (study index date 1) by endocrinologist.
|
T2D Patients From Russian Federation
Patients with type 2 diabetes (T2D) from Russian Federation who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) between September 2018 and December 2018 (study index date 1) and have consented to documentation at study index date 2.
|
|---|---|---|---|---|---|
|
Time to Discontinuation of Type 2 Diabetes (T2D) Treatment According to Study Medication
|
19.46 months
Standard Error 0.73
|
18.28 months
Standard Error 0.44
|
20.61 months
Standard Error 0.62
|
14.04 months
Standard Error 0.12
|
—
|
Adverse Events
T2D Patients From Central Eastern Europe
Serious events: 43 serious events
Other events: 0 other events
Deaths: 0 deaths
Serious adverse events
| Measure |
T2D Patients From Central Eastern Europe
n=4055 participants at risk
Patients with type 2 diabetes (T2D) from Central Eastern Europe (CEE) (Bulgaria, Czech Republic, Hungary, Poland and the Russian Federation) who were newly initiated (first ever use) on empagliflozin or other sodium dependent glucose transporter inhibitor (SGLT2i), dipeptidyl peptidase 4 inhibitor (DPP4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) between September 2018 and December 2018 (study index date 1).
|
|---|---|
|
Gastrointestinal disorders
Abdominal pain
|
0.07%
3/4055 • up to 14 months.
Prescribed patient set (PPS): All patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective T2D medication and whose documentation was electronically signed by the physician. Within this observational study the seriousness of Adverse Events was not collected, therefore the "Total # at Risk by any Other Adverse Events" is "0". All adverse events collected in this study are reported under "Serious Adverse Events".
|
|
Gastrointestinal disorders
Abdominal pain upper
|
0.02%
1/4055 • up to 14 months.
Prescribed patient set (PPS): All patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective T2D medication and whose documentation was electronically signed by the physician. Within this observational study the seriousness of Adverse Events was not collected, therefore the "Total # at Risk by any Other Adverse Events" is "0". All adverse events collected in this study are reported under "Serious Adverse Events".
|
|
Gastrointestinal disorders
Dyspepsia
|
0.05%
2/4055 • up to 14 months.
Prescribed patient set (PPS): All patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective T2D medication and whose documentation was electronically signed by the physician. Within this observational study the seriousness of Adverse Events was not collected, therefore the "Total # at Risk by any Other Adverse Events" is "0". All adverse events collected in this study are reported under "Serious Adverse Events".
|
|
Gastrointestinal disorders
Nausea
|
0.07%
3/4055 • up to 14 months.
Prescribed patient set (PPS): All patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective T2D medication and whose documentation was electronically signed by the physician. Within this observational study the seriousness of Adverse Events was not collected, therefore the "Total # at Risk by any Other Adverse Events" is "0". All adverse events collected in this study are reported under "Serious Adverse Events".
|
|
Gastrointestinal disorders
Vomiting
|
0.05%
2/4055 • up to 14 months.
Prescribed patient set (PPS): All patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective T2D medication and whose documentation was electronically signed by the physician. Within this observational study the seriousness of Adverse Events was not collected, therefore the "Total # at Risk by any Other Adverse Events" is "0". All adverse events collected in this study are reported under "Serious Adverse Events".
|
|
General disorders
Thirst
|
0.02%
1/4055 • up to 14 months.
Prescribed patient set (PPS): All patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective T2D medication and whose documentation was electronically signed by the physician. Within this observational study the seriousness of Adverse Events was not collected, therefore the "Total # at Risk by any Other Adverse Events" is "0". All adverse events collected in this study are reported under "Serious Adverse Events".
|
|
Infections and infestations
Genital infection
|
0.17%
7/4055 • up to 14 months.
Prescribed patient set (PPS): All patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective T2D medication and whose documentation was electronically signed by the physician. Within this observational study the seriousness of Adverse Events was not collected, therefore the "Total # at Risk by any Other Adverse Events" is "0". All adverse events collected in this study are reported under "Serious Adverse Events".
|
|
Infections and infestations
Infection
|
0.02%
1/4055 • up to 14 months.
Prescribed patient set (PPS): All patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective T2D medication and whose documentation was electronically signed by the physician. Within this observational study the seriousness of Adverse Events was not collected, therefore the "Total # at Risk by any Other Adverse Events" is "0". All adverse events collected in this study are reported under "Serious Adverse Events".
|
|
Infections and infestations
Urinary tract infection
|
0.12%
5/4055 • up to 14 months.
Prescribed patient set (PPS): All patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective T2D medication and whose documentation was electronically signed by the physician. Within this observational study the seriousness of Adverse Events was not collected, therefore the "Total # at Risk by any Other Adverse Events" is "0". All adverse events collected in this study are reported under "Serious Adverse Events".
|
|
Infections and infestations
Vulvovaginal candidiasis
|
0.02%
1/4055 • up to 14 months.
Prescribed patient set (PPS): All patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective T2D medication and whose documentation was electronically signed by the physician. Within this observational study the seriousness of Adverse Events was not collected, therefore the "Total # at Risk by any Other Adverse Events" is "0". All adverse events collected in this study are reported under "Serious Adverse Events".
|
|
Infections and infestations
Vulvovaginitis
|
0.12%
5/4055 • up to 14 months.
Prescribed patient set (PPS): All patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective T2D medication and whose documentation was electronically signed by the physician. Within this observational study the seriousness of Adverse Events was not collected, therefore the "Total # at Risk by any Other Adverse Events" is "0". All adverse events collected in this study are reported under "Serious Adverse Events".
|
|
Investigations
Glomerular filtration rate decreased
|
0.02%
1/4055 • up to 14 months.
Prescribed patient set (PPS): All patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective T2D medication and whose documentation was electronically signed by the physician. Within this observational study the seriousness of Adverse Events was not collected, therefore the "Total # at Risk by any Other Adverse Events" is "0". All adverse events collected in this study are reported under "Serious Adverse Events".
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bladder cancer
|
0.02%
1/4055 • up to 14 months.
Prescribed patient set (PPS): All patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective T2D medication and whose documentation was electronically signed by the physician. Within this observational study the seriousness of Adverse Events was not collected, therefore the "Total # at Risk by any Other Adverse Events" is "0". All adverse events collected in this study are reported under "Serious Adverse Events".
|
|
Nervous system disorders
Cerebrovascular accident
|
0.02%
1/4055 • up to 14 months.
Prescribed patient set (PPS): All patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective T2D medication and whose documentation was electronically signed by the physician. Within this observational study the seriousness of Adverse Events was not collected, therefore the "Total # at Risk by any Other Adverse Events" is "0". All adverse events collected in this study are reported under "Serious Adverse Events".
|
|
Renal and urinary disorders
Dysuria
|
0.27%
11/4055 • up to 14 months.
Prescribed patient set (PPS): All patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective T2D medication and whose documentation was electronically signed by the physician. Within this observational study the seriousness of Adverse Events was not collected, therefore the "Total # at Risk by any Other Adverse Events" is "0". All adverse events collected in this study are reported under "Serious Adverse Events".
|
|
Renal and urinary disorders
Pollakiuria
|
0.10%
4/4055 • up to 14 months.
Prescribed patient set (PPS): All patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective T2D medication and whose documentation was electronically signed by the physician. Within this observational study the seriousness of Adverse Events was not collected, therefore the "Total # at Risk by any Other Adverse Events" is "0". All adverse events collected in this study are reported under "Serious Adverse Events".
|
|
Reproductive system and breast disorders
Balanoposthitis
|
0.17%
7/4055 • up to 14 months.
Prescribed patient set (PPS): All patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective T2D medication and whose documentation was electronically signed by the physician. Within this observational study the seriousness of Adverse Events was not collected, therefore the "Total # at Risk by any Other Adverse Events" is "0". All adverse events collected in this study are reported under "Serious Adverse Events".
|
Other adverse events
Adverse event data not reported
Additional Information
Boehringer Ingelheim, Call Center
Boehringer Ingelheim
Phone: 1-800-243-0127
Email: [email protected]
Results disclosure agreements
- Principal investigator is a sponsor employee Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.
- Publication restrictions are in place
Restriction type: OTHER